George Perry

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5528737/publications.pdf

Version: 2024-02-01

905	77,897	355 136	872 243
papers	citations	h-index	g-index

1121	1121	1121	60025
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Potential longâ€term effect of tumor necrosis factor inhibitors on dementia risk: A propensity score matched retrospective cohort study in US veterans. Alzheimer's and Dementia, 2022, 18, 1248-1259.	0.4	7
2	Immune modulations and immunotherapies for Alzheimerâ€™s disease: a comprehensive review. Reviews in the Neurosciences, 2022, 33, 365-381.	1.4	5
3	Conformation- and phosphorylation-dependent electron tunnelling across self-assembled monolayers of tau peptides. Journal of Colloid and Interface Science, 2022, 606, 2038-2050.	5.0	2
4	Optogenetics: implications for Alzheimerâ€™s disease research and therapy. Molecular Brain, 2022, 15, 20.	1.3	14
5	Hyperphosphorylated Tau Relates to Improved Cognitive Performance and Reduced Hippocampal Excitability in the Young rTg4510 Mouse Model of Tauopathy. Journal of Alzheimer's Disease, 2022, , 1-15.	1.2	4
6	Hypoxic Preconditioning Averts Sporadic Alzheimer's Disease-Like Phenotype in Rats: A Focus on Mitochondria. Antioxidants and Redox Signaling, 2022, 37, 739-757.	2.5	6
7	Making the Case for Accelerated Withdrawal of Aducanumab. Journal of Alzheimer's Disease, 2022, 87, 1003-1007.	1.2	19
8	Now is the Time to Improve Cognitive Screening and Assessment for Clinical and Research Advancement. Journal of Alzheimer's Disease, 2022, 87, 305-315.	1.2	11
9	Preventive and Therapeutic Strategies in Alzheimer's Disease: Focus on Oxidative Stress, Redox Metals, and Ferroptosis. Antioxidants and Redox Signaling, 2021, 34, 591-610.	2.5	86
10	Reactive Oxygen Species and Their Impact in Neurodegenerative Diseases: Literature Landscape Analysis. Antioxidants and Redox Signaling, 2021, 34, 402-420.	2.5	69
11	A Multilevel View of the Development of Alzheimerâ€™s Disease. Neuroscience, 2021, 457, 283-293.	1.1	43
12	MMR Vaccination: A Potential Strategy to Reduce Severity and Mortality of COVID-19 Illness. American Journal of Medicine, 2021, 134, 153-155.	0.6	30
13	Dietary flavonoids: Nano delivery and nanoparticles for cancer therapy. Seminars in Cancer Biology, 2021, 69, 150-165.	4.3	71
14	MSDC-0160 and MSDC-0602 Binding with Human Mitochondrial Pyruvate Carrier (MPC) 1 and 2 Heterodimer. , 2021, , 427-455.		0
15	Alzheimerâ€™s and Consciousness: How Much Subjectivity Is Objective?. Neuroscience Insights, 2021, 16, 263310552110338.	0.9	1
16	Strawberry (Fragaria ananassa duch.) Alba extract attenuates DNA damage in lymphocytes of patients with Alzheimerâ€™s disease. Journal of Food Biochemistry, 2021, 45, e13637.	1.2	2
17	Molecular Processing of Tau Protein in Progressive Supranuclear Palsy: Neuronal and Glial Degeneration. Journal of Alzheimer's Disease, 2021, 79, 1517-1531.	1.2	8
18	Challenges and Strategies of Successful Mentoring: The Perspective of LEADS Scholars and Mentors from Minority Serving Institutions. International Journal of Environmental Research and Public Health, 2021, 18, 6155.	1.2	9

#	Article	IF	Citations
19	Biogenic metallic elements in the human brain?. Science Advances, 2021, 7, .	4.7	48
20	Community Engagement Practices at Research Centers in U.S. Minority Institutions: Priority Populations and Innovative Approaches to Advancing Health Disparities Research. International Journal of Environmental Research and Public Health, 2021, 18, 6675.	1.2	6
21	Oxidative Stress Signaling in Blast TBI-Induced Tau Phosphorylation. Antioxidants, 2021, 10, 955.	2.2	10
22	Omics sciences for systems biology in Alzheimerâ€™s disease: State-of-the-art of the evidence. Ageing Research Reviews, 2021, 69, 101346.	5.0	74
23	Akin to the Great Revolutions of Ages, the Combinatorial Approach for Preempting Genetic Diseases Requires the Confluence of Independent Scientific and Societal Developments Emerging from Synergisms Between Serendipitous, Planned and Natural Progressions Significantly Magnifying the Impact Over the Simple Sum of their Individual Components or Subfields. Acta Scientific Microbiology, 2021, 4, 105-120.	0.0	0
24	Indoles as essential mediators in the gut-brain axis. Their role in Alzheimer's disease. Neurobiology of Disease, 2021, 156, 105403.	2.1	39
25	The Amyloid-Î² Pathway in Alzheimerâ€™s Disease. Molecular Psychiatry, 2021, 26, 5481-5503.	4.1	478
26	American Dementia: Brain Health in an Unhealthy Society by Daniel R. George and Peter J. Whitehouse, Johns Hopkins Press, 2021, 390 pp.. Journal of Alzheimer's Disease, 2021, 83, 935-935.	1.2	0
27	Alzheimer's and Parkinson's Disease Novel Therapeutic Target. , 2021, , 411-426.		0
28	Alzheimer's Disease Pharmacology. , 2021, , .		1
29	Mitochondrial Fusion Suppresses Tau Pathology-Induced Neurodegeneration and Cognitive Decline. Journal of Alzheimer's Disease, 2021, 84, 1057-1069.	1.2	6
30	Gutâ€“microbiotaâ€“microgliaâ€“brain interactions in Alzheimerâ€™s disease: knowledge-based, multi-dimensional characterization. Alzheimer's Research and Therapy, 2021, 13, 177.	3.0	15
31	SWADESH: A Comprehensive Platform for Multimodal Data and Analytics for Advanced Research in Alzheimerâ€™s Disease and Other Brain Disorders. Journal of Alzheimer's Disease, 2021, , 1-5.	1.2	4
32	Editorial: Oxidative Stress Revisitedâ€”Major Role in Vascular Diseases, Volume II. Frontiers in Physiology, 2021, 12, 826129.	1.3	0
33	Functional study in the young rTg4510 mouse model of tauopathy. Alzheimer's and Dementia, 2021, 17, e058539.	0.4	0
34	Role of ferroptosis iron-dependent cell death in neurodegenerative processes.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e055243.	0.4	1
35	TDP-43 inhibitory peptide alleviates neurodegeneration and memory loss in an APP transgenic mouse model for Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165580.	1.8	17
36	Status and future directions of clinical trials in Alzheimer's disease. International Review of Neurobiology, 2020, 154, 3-50.	0.9	29

#	Article	IF	Citations
37	Toll-like receptors in Alzheimer's disease. Journal of Neuroimmunology, 2020, 348, 577362.	1.1	35
38	Association of plasma YKL-40 with brain amyloid-Î² levels, memory performance, and sex in subjective memory complainers. Neurobiology of Aging, 2020, 96, 22-32.	1.5	18
39	A brief guide to the science and art of writing manuscripts in biomedicine. Journal of Translational Medicine, 2020, 18, 425.	1.8	23
40	Decreased salivary lactoferrin levels are specific to Alzheimer's disease. EBioMedicine, 2020, 57, 102834.	2.7	59
41	The Interrelation of Neurological and Psychological Symptoms of COVID-19: Risks and Remedies. Journal of Clinical Medicine, 2020, 9, 2624.	1.0	12
42	Ethanol-Fixed, Paraffin-Embedded Tissue Imaging: Implications for Alzheimerâ€™s Disease Research. Journal of the American Society for Mass Spectrometry, 2020, 31, 2416-2420.	1.2	5
43	RNA and Oxidative Stress in Alzheimerâ€™s Disease: Focus on microRNAs. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-16.	1.9	66
44	Decreased salivary lactoferrin levels are specific to Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e042621.	0.4	1
45	Î±-Synuclein and tau, two targets for dementia. Studies in Natural Products Chemistry, 2020, 67, 1-25.	0.8	6
46	Mitochondria dysfunction in the pathogenesis of Alzheimerâ€™s disease: recent advances. Molecular Neurodegeneration, 2020, 15, 30.	4.4	562
47	The Role of the Microbiotaâ€“Gutâ€“Brain Axis and Antibiotics in ALS and Neurodegenerative Diseases. Microorganisms, 2020, 8, 784.	1.6	37
48	Analysis of the Relationship Between Metalloprotease-9 and Tau Protein in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 76, 553-569.	1.2	10
49	Role of antioxidants and a nutrient rich diet in Alzheimer's disease. Open Biology, 2020, 10, 200084.	1.5	39
50	National Dementia BioBank: A Strategy for the Diagnosis and Study of Neurodegenerative Diseases in MÃ©xico. Journal of Alzheimer's Disease, 2020, 76, 853-862.	1.2	3
51	Alzheimerâ€™s Disease Patients in the Crosshairs of COVID-19. Journal of Alzheimer's Disease, 2020, 76, 1-1.	1.2	17
52	Polyphenols in Alzheimerâ€™s Disease and in the Gutâ€“Brain Axis. Microorganisms, 2020, 8, 199.	1.6	66
53	The Microbiotaâ€“Gutâ€“Brain Axisâ€“Heart Shunt Part II: Prosaic Foods and the Brainâ€“Heart Connection in Alzheimer Disease. Microorganisms, 2020, 8, 493.	1.6	19
54	Unraveling the Role of Mitochondria in Alzheimerâ€™s Disease. , 2020, , 407-430.		1

#	Article	IF	Citations
55	Hippocampal Unicellular Recordings and Hippocampal-dependent Innate Behaviors in an Adolescent Mouse Model of Alzheimerâ€™s disease. Bio-protocol, 2020, 10, e3529.	0.2	2
56	INVITED ARTICLE FROM THE 2020 TEXAS ACADEMY OF SCIENCE TEXAS DISTINGUISHED SCIENTIST. Texas Journal of Science, 2020, 72, .	0.3	0
57	Implication of ferroptosis ironâ€dependent programmed cell death mechanism in neurodegeneration. Alzheimer's and Dementia, 2020, 16, e043978.	0.4	5
58	Differences in structure and function between human and murine tau. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 2024-2030.	1.8	22
59	Neuroprotective and Antioxidant Effect of Ginkgo biloba Extract Against AD and Other Neurological Disorders. Neurotherapeutics, 2019, 16, 666-674.	2.1	191
60	Phospho-Tau Protein Expression in the Cell Cycle of SH-SY5Y Neuroblastoma Cells: A Morphological Study. Journal of Alzheimer's Disease, 2019, 71, 631-645.	1.2	9
61	Editorial: Oxidative Stress Revisitedâ€”Major Role in Vascular Diseases. Frontiers in Physiology, 2019, 10, 788.	1.3	2
62	Neuropsychiatric Disturbances and Diabetes Mellitus: The Role of Oxidative Stress. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-2.	1.9	13
63	Neuropathology in Consecutive Forensic Consultation Cases with a History of Remote Traumatic Brain Injury. Journal of Alzheimer's Disease, 2019, 72, 683-691.	1.2	3
64	Chronic traumatic encephalopathy neuropathology might not be inexorably progressive or unique to repetitive neurotrauma. Brain, 2019, 142, 3672-3693.	3.7	57
65	TDP-43 proteinopathy and mitochondrial abnormalities in neurodegeneration. Molecular and Cellular Neurosciences, 2019, 100, 103396.	1.0	62
66	Gait Disorders in Alzheimerâ€™s Disease and Other Dementias: There is Something in the Way You Walk. Journal of Alzheimer's Disease, 2019, 71, S1-S4.	1.2	9
67	Current research in biotechnology: Exploring the biotech forefront. Current Research in Biotechnology, 2019, 1, 34-40.	1.9	17
68	Single-channel permeability and glycerol affinity of human aquaglyceroporin AQP3. Biochimica Et Biophysica Acta - Biomembranes, 2019, 1861, 768-775.	1.4	20
69	Lithium as a Treatment for Alzheimerâ€™s Disease: The Systems Pharmacology Perspective. Journal of Alzheimer's Disease, 2019, 69, 615-629.	1.2	44
70	Inhibition of Calpain Protects Against Tauopathy in Transgenic P301S Tau Mice. Journal of Alzheimer's Disease, 2019, 69, 1077-1087.	1.2	9
71	Plasma amyloid Î² 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 764-775.	0.4	122
72	The Research Centers in Minority Institutions (RCMI) Translational Research Network: Building and Sustaining Capacity for Multi-Site Basic Biomedical, Clinical and Behavioral Research. Ethnicity and Disease, 2019, 29, 135-144.	1.0	25

#	Article	IF	Citations
73	Meet Our Co-Editor. Mini-Reviews in Medicinal Chemistry, 2019, 19, 449-449.	1.1	0
74	Rapid method towards proteomic analysis of dried blood spots by MALDI mass spectrometry. Clinical Mass Spectrometry, 2019, 12, 30-36.	1.9	2
75	The Transformative Possibilities of the Microbiota and Mycobiota for Health, Disease, Aging, and Technological Innovation.. Biomedicines, 2019, 7, 24.	1.4	25
76	The Alzheimer Precision Medicine Initiative. Journal of Alzheimer's Disease, 2019, 68, 1-24.	1.2	75
77	Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study. Alzheimer's Research and Therapy, 2019, 11, 15.	3.0	24
78	Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology, 2019, 92, 329-337.	1.5	194
79	No Evidence of Increased Chronic Traumatic Encephalopathy Pathology or Neurodegenerative Proteinopathy in Former Military Service Members: A Preliminary Study. Journal of Alzheimer's Disease, 2019, 67, 1277-1289.	1.2	13
80	The amyloid cascade and Alzheimer's disease therapeutics: theory versus observation. Laboratory Investigation, 2019, 99, 958-970.	1.7	82
81	P4â€513: ACTIVATION OF FERROPTOSIS, AN IRONâ€DEPENDENT FORM OF NONâ€APOPTOTIC DEATH IN NEURONS. Alzheimer's and Dementia, 2019, 15, P1510.	0.4	0
82	Tau Biology, Tauopathy, Traumatic Brain Injury, and Diagnostic Challenges. Journal of Alzheimer's Disease, 2019, 67, 447-467.	1.2	73
83	Diminished O-GlcNAcylation in Alzheimer's disease is strongly correlated with mitochondrial anomalies. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 2048-2059.	1.8	48
84	Analysis of post-translational modifications in Alzheimer's disease by mass spectrometry. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 2040-2047.	1.8	15
85	The sterol regulatory elementâ€binding protein 2 is dysregulated by tau alterations in Alzheimer disease. Brain Pathology, 2019, 29, 530-543.	2.1	11
86	MAPK signalling pathway in cancers: Olive products as cancer preventive and therapeutic agents. Seminars in Cancer Biology, 2019, 56, 185-195.	4.3	105
87	Transplantation of Human Chorion-Derived Cholinergic Progenitor Cells: a Novel Treatment for Neurological Disorders. Molecular Neurobiology, 2019, 56, 307-318.	1.9	10
88	Pathomechanisms of TDPâ€43 in neurodegeneration. Journal of Neurochemistry, 2018, 146, 7-20.	2.1	157
89	Nanoscale synchrotron X-ray speciation of iron and calcium compounds in amyloid plaque cores from Alzheimer's disease subjects. Nanoscale, 2018, 10, 11782-11796.	2.8	88
90	Phosphorylation of Tau protein correlates with changes in hippocampal theta oscillations and reduces hippocampal excitability in Alzheimer's model. Journal of Biological Chemistry, 2018, 293, 8462-8472.	1.6	59

#	Article	IF	Citations
91	Precision pharmacology for Alzheimerâ€™s disease. Pharmacological Research, 2018, 130, 331-365.	3.1	79
92	Expression of growth hormone gene in the baboon eye. Experimental Eye Research, 2018, 169, 157-169.	1.2	8
93	IronÂ·ic facts about dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 446-447.	0.9	3
94	Markers of oxidative damage to lipids, nucleic acids and proteins and antioxidant enzymes activities in Alzheimer's disease brain: A meta-analysis in human pathological specimens. Free Radical Biology and Medicine, 2018, 115, 351-360.	1.3	78
95	Characterization of Proteins Present in Isolated Senile Plaques from Alzheimerâ€™s Diseased Brains by MALDI-TOF MS with MS/MS. ACS Chemical Neuroscience, 2018, 9, 708-714.	1.7	12
96	Rab10 Phosphorylation is a Prominent Pathological Feature in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 63, 157-165.	1.2	29
97	Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology. Journal of Alzheimer's Disease, 2018, 64, S47-S105.	1.2	122
98	Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study. Alzheimer's and Dementia, 2018, 14, 280-292.	0.4	246
99	Thermodynamics of Amyloid-Î² Fibril Elongation: Atomistic Details of the Transition State. ACS Chemical Neuroscience, 2018, 9, 783-789.	1.7	33
100	Incubation with Cu(II) and Zn(II) salts enhances MALDIâ€TOF mass spectra of amyloidâ€beta and Î±â€synuclein toward in vivo analysis. Journal of Mass Spectrometry, 2018, 53, 162-171.	0.7	4
101	Preface. Mini-Reviews in Medicinal Chemistry, 2018, 19, 2-2.	1.1	0
102	Preface: Alzheimerâ€™s Disease: New Beginnings. Journal of Alzheimer's Disease, 2018, 64, S1-S1.	1.2	0
103	Vascular Oxidative Stress: Impact and Therapeutic Approaches. Frontiers in Physiology, 2018, 9, 1668.	1.3	158
104	Birth of JAD: 20 Years Later. Journal of Alzheimer's Disease, 2018, 62, 901-901.	1.2	1
105	Expression Profiling of Cytokine, Cholinergic Markers, and Amyloid-Î² Deposition in the APPSWE/PS1dE9 Mouse Model of Alzheimerâ€™s Disease Pathology. Journal of Alzheimer's Disease, 2018, 62, 467-476.	1.2	18
106	Genetic Risk of Alzheimerâ€™s Disease: Three Wishes Now That the Genie is Out of the Bottle. Journal of Alzheimer's Disease, 2018, 66, 421-423.	1.2	3
107	An Inducible Alpha-Synuclein Expressing Neuronal Cell Line Model for Parkinsonâ€™s Disease1. Journal of Alzheimer's Disease, 2018, 66, 453-460.	1.2	11
108	From Oxidative Stress to Ageing via Lifestyle, Nutraceuticals, Polypharmacy, and Neuropsychological Factors. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-2.	1.9	6

#	Article	IF	Citations
109	Drug-Abuse Nanotechnology: Opportunities and Challenges. ACS Chemical Neuroscience, 2018, 9, 2288-2298.	1.7	7
110	Putative Gonadotropin-Releasing Hormone Agonist Therapy and Dementia: An Application of Medicare Hospitalization Claims Data. Journal of Alzheimer's Disease, 2018, 63, 1269-1277.	1.2	4
111	Evaluation of Metabolic and Synaptic Dysfunction Hypotheses of Alzheimer's Disease (AD): A Meta-Analysis of CSF Markers. Current Alzheimer Research, 2018, 15, 164-181.	0.7	49
112	Association of cerebrospinal fluid Î±â€synuclein with total and phosphoâ€tau‹sub›181‹/sub› protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers. Alzheimer's and Dementia, 2018, 14, 1623-1631.	0.4	45
113	Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer's disease in cognitively normal older adults with subjective memory complaints. Alzheimer's and Dementia, 2018, 14, 1204-1215.	0.4	79
114	Mitofusin 2 Regulates Axonal Transport of Calpastatin to Prevent Neuromuscular Synaptic Elimination in Skeletal Muscles. Cell Metabolism, 2018, 28, 400-414.e8.	7.2	39
115	Mfn2 ablation causes an oxidative stress response and eventual neuronal death in the hippocampus and cortex. Molecular Neurodegeneration, 2018, 13, 5.	4.4	77
116	Towards an Integrative Understanding of tRNA Aminoacylationâ€“Dietâ€“Hostâ€“Gut Microbiome Interactions in Neurodegeneration. Nutrients, 2018, 10, 410.	1.7	17
117	Gibbs Free-Energy Gradient along the Path of Glucose Transport through Human Glucose Transporter 3. ACS Chemical Neuroscience, 2018, 9, 2815-2823.	1.7	13
118	Clinical biomarkers for cancer recognition and prevention: A novel approach with optical measurements. Cancer Biomarkers, 2018, 22, 179-198.	0.8	2
119	Anthocyanins: Multi-Target Agents for Prevention and Therapy of Chronic Diseases. Current Pharmaceutical Design, 2018, 23, 6321-6346.	0.9	32
120	Nutritional supplements and dementia. Clinical Nutrition, 2017, 36, 613-614.	2.3	0
121	Identification of Inhibitors of CD36-Amyloid Beta Binding as Potential Agents for Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2017, 8, 1232-1241.	1.7	35
122	Elongation affinity, activation barrier, and stability of AÎ²42 oligomers/fibrils in physiological saline. Biochemical and Biophysical Research Communications, 2017, 487, 444-449.	1.0	13
123	The Vascular Impairment of Cognition Classification Consensus Study. Alzheimer's and Dementia, 2017, 13, 624-633.	0.4	143
124	Affinity and path of binding xylopyranose unto E.Âcoli xylose permease. Biochemical and Biophysical Research Communications, 2017, 494, 202-206.	1.0	10
125	Dementia Pugilistica Revisited. Journal of Alzheimer's Disease, 2017, 60, 1209-1221.	1.2	30
126	Inhibition of mitochondrial fragmentation protects against Alzheimerâ€™s disease in rodent model. Human Molecular Genetics, 2017, 26, 4118-4131.	1.4	123

#	Article	IF	Citations
127	Consequences of RNA oxidation on protein synthesis rate and fidelity: implications for the pathophysiology of neuropsychiatric disorders. Biochemical Society Transactions, 2017, 45, 1053-1066.	1.6	43
128	Rosmarinic acid prevents fibrillization and diminishes vibrational modes associated to Î² sheet in tau protein linked to Alzheimerâ€™s disease. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 945-953.	2.5	63
129	Advances in Alzheimerâ€™s Diagnosis and Therapy: The Implications of Nanotechnology. Trends in Biotechnology, 2017, 35, 937-953.	4.9	121
130	Asking the Right Questions. Negotiation Journal, 2017, 33, 375-378.	0.3	0
131	The Need to Separate Chronic Traumatic Encephalopathy Neuropathology from Clinical Features. Journal of Alzheimer's Disease, 2017, 61, 17-28.	1.2	47
132	Antioxidants in theÂPrevention and Treatment of Alzheimerâ€™s Disease. , 2017, , 523-553.		2
133	MSDC-0160 and MSDC-0602 Binding with Human Mitochondrial Pyruvate Carrier (MPC) 1 and 2 Heterodimer. International Journal of Knowledge Discovery in Bioinformatics, 2017, 7, 43-67.	0.8	7
134	Alzheimer's and Parkinson's Disease Novel Therapeutic Target. International Journal of Knowledge Discovery in Bioinformatics, 2017, 7, 68-82.	0.8	2
135	Tau Proteins. , 2017, , 145-160.		1
136	Molecular Pathways in Normal Aging andÂNeurodegeneration: Mechanisms andÂTherapeutics. Journal of Alzheimer's Disease, 2017, 60, S1-S2.	1.2	1
137	Meet Our Editor. Letters in Drug Design and Discovery, 2017, 14, 251-251.	0.4	0
138	BARHL1 Is Downregulated in Alzheimerâ€™s Disease and May Regulate Cognitive Functions through ESR1 and Multiple Pathways. Genes, 2017, 8, 245.	1.0	57
139	Slower Dynamics and Aged Mitochondria in Sporadic Alzheimerâ€™s Disease. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-14.	1.9	95
140	Metals and Mitochondria in Neurodegeneration. , 2017, , 283-311.		0
141	Preface. Mini-Reviews in Medicinal Chemistry, 2017, 18, 2.	1.1	0
142	TMEM230 Accumulation in Granulovacuolar Degeneration Bodies and Dystrophic Neurites of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 58, 1027-1033.	1.2	9
143	Meet Our Co-Editor. Mini-Reviews in Medicinal Chemistry, 2017, 17, 319-319.	1.1	0
144	Meet Our Editor. Current Clinical Pharmacology, 2017, 12, .	0.2	0

#	Article	IF	Citations
145	Enhanced Phosphorylation of Bax and Its Translocation into Mitochondria in the Brains of Individuals Affiliated with Alzheimerâ€™s Disease. The Open Neurology Journal, 2017, 11, 48-58.	0.4	12
146	The Four Pillars of Alzheimer's Prevention. Cerebrum: the Dana Forum on Brain Science, 2017, 2017, .	0.1	6
147	Alzheimer disease research in the 21st century: past and current failures, new perspectives and funding priorities. Oncotarget, 2016, 7, 38999-39016.	0.8	56
148	Overview of Alzheimerâ€™s Disease and Some Therapeutic Approaches Targeting AÎ²by Using Several Synthetic and Herbal Compounds. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-22.	1.9	126
149	Behavioral Abnormality Induced by Enhanced Hypothalamo-Pituitary-Adrenocortical Axis Activity under Dietary Zinc Deficiency and Its Usefulness as a Model. International Journal of Molecular Sciences, 2016, 17, 1149.	1.8	13
150	Promise from the Sea. Marine Drugs, 2016, 14, 178.	2.2	2
151	Loss of JAM-C leads to impaired esophageal innervations and megaesophagus in mice. Ecological Management and Restoration, 2016, 29, 864-871.	0.2	4
152	1,3-propanediol binds deep inside the channel to inhibit water permeation through aquaporins. Protein Science, 2016, 25, 433-441.	3.1	7
153	Modulation of Parkinsonâ€™s Disease Associated Protein Rescues Alzheimerâ€™s Disease Degeneration. Journal of Alzheimer's Disease, 2016, 55, 73-75.	1.2	6
154	Fibrillar Amyloid-Î² Accumulation Triggers an Inflammatory Mechanism Leading to Hyperphosphorylation of the Carboxyl-Terminal End of Tau Polypeptide in the Hippocampal Formation of the 3Ã—Tg-AD Transgenic Mouse. Journal of Alzheimer's Disease, 2016, 52, 243-269.	1.2	19
155	Estrogen receptor-Î± is localized to neurofibrillary tangles in Alzheimerâ€™s disease. Scientific Reports, 2016, 6, 20352.	1.6	45
156	High-resolution analytical imaging and electron holography of magnetite particles in amyloid cores of Alzheimerâ€™s disease. Scientific Reports, 2016, 6, 24873.	1.6	103
157	Meta-analysis of Telomere Length in Alzheimerâ€™s Disease. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 71, 1069-1073.	1.7	173
158	Mitochondrial traffic jams in Alzheimer's disease - pinpointing the roadblocks. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 1909-1917.	1.8	73
159	Selenoprotein S Reduces Endoplasmic Reticulum Stress-Induced Phosphorylation of Tau: Potential Role in Selenate Mitigation of Tau Pathology. Journal of Alzheimer's Disease, 2016, 55, 749-762.	1.2	34
160	Microbes and Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 51, 979-984.	1.2	426
161	Betaâ€amyloid 1â€42 monomers, but not oligomers, produce <scp>PHF</scp> â€like conformation of Tau protein. Aging Cell, 2016, 15, 914-923.	3.0	27
162	Nucleic acid oxidative damage in Alzheimer's diseaseâ€”explained by the hepcidin-ferroportin neuronal iron overload hypothesis?. Journal of Trace Elements in Medicine and Biology, 2016, 38, 1-9.	1.5	36

#	Article	IF	Citations
163	ESCRT-0 dysfunction compromises autophagic degradation of protein aggregates and facilitates ER stress-mediated neurodegeneration via apoptotic and necroptotic pathways. Scientific Reports, 2016, 6, 24997.	1.6	53
164	In vivo visualization of tau deposits in corticobasal syndrome by ¹⁸ F-THK5351 PET. Neurology, 2016, 87, 2309-2316.	1.5	105
165	Morphometric analysis of cryofixed muscular tissue for intraoperative consultation. Microscopy Research and Technique, 2016, 79, 155-161.	1.2	0
166	Tackling Alzheimerâ€™s Disease by Targeting Oxidative Stress and Mitochondria. , 2016, , 477-502.		1
167	Insights into the structural patterns of the antileishmanial activity of bi- and tricyclic N-heterocycles. Organic and Biomolecular Chemistry, 2016, 14, 7053-7060.	1.5	12
168	Scientific Information Security in Information Science and Academic Publishing. Artificial Organs, 2016, 40, 425-430.	1.0	1
169	Cerebrovascular and mitochondrial abnormalities in Alzheimerâ€™s disease: a brief overview. Journal of Neural Transmission, 2016, 123, 107-111.	1.4	14
170	Subgroup differences in â€˜brain-typeâ€™ transferrin and Î±-synuclein in Parkinsonâ€™s disease and multiple system atrophy. Journal of Biochemistry, 2016, 160, 87-91.	0.9	7
171	Prefrontal white matter pathology in air pollution exposed Mexico City young urbanites and their potential impact on neurovascular unit dysfunction and the development of Alzheimer's disease. Environmental Research, 2016, 146, 404-417.	3.7	135
172	PARK2 enhancement is able to compensate mitophagy alterations found in sporadic Alzheimer's disease. Human Molecular Genetics, 2016, 25, 792-806.	1.4	134
173	Telomere length in Parkinson's disease: A meta-analysis. Experimental Gerontology, 2016, 75, 53-55.	1.2	51
174	Laser-Induced In-Source Decay Applied to the Determination of Amyloid-Beta in Alzheimerâ€™s Brains. ACS Chemical Neuroscience, 2016, 7, 261-268.	1.7	22
175	Current needs for human and medical genomics research infrastructure in low and middle income countries: TableÂ1. Journal of Medical Genetics, 2016, 53, 438-440.	1.5	19
176	Loss of awareness of hyposmia is associated with mild cognitive impairment in Parkinson's disease. Parkinsonism and Related Disorders, 2016, 22, 74-79.	1.1	33
177	Dysfunctional tubular endoplasmic reticulum constitutes a pathological feature of Alzheimerâ€™s disease. Molecular Psychiatry, 2016, 21, 1263-1271.	4.1	35
178	Oxidative Stress and Alzheimerâ€™s Disease. Oxidative Stress in Applied Basic Research and Clinical Practice, 2016, , 189-198.	0.4	8
179	Oxidative Stress and Neuropsychiatric Disorders in the Life Spectrum. , 2016, , 157-166.		1
180	Tau, Amyloid Beta and Deep Brain Stimulation: Aiming to Restore Cognitive Deficit in Alzheimer's Disease. Current Alzheimer Research, 2016, 14, 40-46.	0.7	16

#	Article	IF	Citations
181	Oxidative Stress Induces Senescence in Cultured RPE Cells. The Open Neurology Journal, 2016, 10, 83-87.	0.4	22
182	Molecular Mapping Alzheimer's Disease: MALDI Imaging of Formalin-fixed, Paraffin-embedded Human Hippocampal Tissue. The Open Neurology Journal, 2016, 10, 88-98.	0.4	9
183	The Role of the Iron Stain in Assessing Intracranial Hemorrhage. The Open Neurology Journal, 2016, 10, 136-142.	0.4	6
184	Functional and Genomic Features of Human Genes Mutated in Neuropsychiatric Disorders. The Open Neurology Journal, 2016, 10, 143-148.	0.4	5
185	P3-029: Oxidative damage is correlated with mitochondrial autophagy. , 2015, 11, P630-P630.		0
186	Chronic Effects of Mild Neurotrauma. Journal of Neuropathology and Experimental Neurology, 2015, 74, 493-499.	0.9	34
187	Preventive Effect of 3,5-dihydroxy-4-methoxybenzyl Alcohol (DHMBA) and Zinc, Components of the Pacific Oyster Crassostrea gigas, on Glutamatergic Neuron Activity in the Hippocampus. Biological Bulletin, 2015, 229, 282-288.	0.7	3
188	Melanin production through novel processing of proopiomelanocortin in the extracellular compartment of the auricular skin of C57BL/6 mice after UV-irradiation. Scientific Reports, 2015, 5, 14579.	1.6	21
189	A Clinical Study of Lupron Depot in the Treatment of Women with Alzheimer's Disease: Preservation of Cognitive Function in Patients Taking an Acetylcholinesterase Inhibitor and Treated with High Dose Lupron Over 48 Weeks. Journal of Alzheimer's Disease, 2015, 44, 549-560.	1.2	47
190	P2-152: Molecular mapping of Alzheimer's disease: Imaging mass spectrometry. , 2015, 11, P545-P545.		0
191	Geometric complexity identifies platelet activation in familial hypercholesterolemic patients. Microscopy Research and Technique, 2015, 78, 519-522.	1.2	3
192	Modification of hippocampal excitability in brain slices pretreated with a low nanomolar concentration of Zn²⁺. Journal of Neuroscience Research, 2015, 93, 1641-1647.	1.3	1
193	Mitochondrial dynamic abnormalities in amyotrophic lateral sclerosis. Translational Neurodegeneration, 2015, 4, 14.	3.6	51
194	Entropy of corneal nerve fibers distribution observed by laser scanning confocal microscopy: A noninvasive quantitative method to characterize the corneal innervation in <scp>S</scp>jogren's syndrome patients. Microscopy Research and Technique, 2015, 78, 1069-1074.	1.2	9
195	Geometric complexity is increased in in vitro activated platelets. Microscopy Research and Technique, 2015, 78, 485-488.	1.2	2
196	Simultaneous Onset of Alzheimerâ€™s Disease in a Husband and Wife in Their Mid-Fifties: What Do We Really Know About Environmental Factors?. The Open Neurology Journal, 2015, 9, 1-3.	0.4	1
197	Two Hundred Treasured Issues!. Journal of Alzheimer's Disease, 2015, 44, 725-725.	1.2	0
198	Miro1 deficiency in amyotrophic lateral sclerosis. Frontiers in Aging Neuroscience, 2015, 7, 100.	1.7	55

#	Article	IF	Citations
199	Alternative neural circuitry that might be impaired in the development of Alzheimer disease. Frontiers in Neuroscience, 2015, 9, 145.	1.4	7
200	RaÃºl Mena: 1953â€“2014. Journal of Alzheimer's Disease, 2015, 45, 325-327.	1.2	1
201	Mexico City normal weight children exposed to high concentrations of ambient PM2.5 show high blood leptin and endothelin-1, vitamin D deficiency, and food reward hormone dysregulation versus low pollution controls. Relevance for obesity and Alzheimer disease. Environmental Research, 2015, 140, 579-592.	3.7	77
202	Direction-sensitive dark matter search with gaseous tracking detector NEWAGE-0.3b'. Progress of Theoretical and Experimental Physics, 2015, 2015, 43F01-0.	1.8	34
203	Regulation of extracellular Zn²⁺homeostasis in the hippocampus as a therapeutic target for Alzheimerâ€™s disease. Expert Opinion on Therapeutic Targets, 2015, 19, 1051-1058.	1.5	9
204	Chlamydia pneumoniae promotes dysfunction of pancreatic beta cells. Cellular Immunology, 2015, 295, 83-91.	1.4	7
205	Curcumin/Melatonin Hybrid 5-(4-Hydroxy-phenyl)-3-oxo-pentanoic Acid [2-(5-Methoxy-1H-indol-3-yl)-ethyl]-amide Ameliorates AD-Like Pathology in the APP/PS1 Mouse Model. ACS Chemical Neuroscience, 2015, 6, 1393-1399.	1.7	51
206	Is interaction of amyloid Î²-peptides with metals involved in cognitive activity?. Metallomics, 2015, 7, 1205-1212.	1.0	18
207	From Neurodegeneration to Brain Health: AnÂIntegrated Approach. Journal of Alzheimer's Disease, 2015, 46, 271-283.	1.2	6
208	Posttranslational modifications of Î±-tubulin in alzheimer disease. Translational Neurodegeneration, 2015, 4, 9.	3.6	88
209	Magnitude and Kinetics of CD8+ T Cell Activation during Hyperacute HIV Infection Impact Viral Set Point. Immunity, 2015, 43, 591-604.	6.6	234
210	Autophagy in Alzheimerâ€™s disease: A Cleaning Service Out-of-order?. Current Topics in Neurotoxicity, 2015, , 123-142.	0.4	0
211	Alterations of the X Chromosome in Lymphocytes of Alzheimerâ€™s Disease Patients. Current Alzheimer Research, 2015, 12, 990-996.	0.7	7
212	Low Dose Pioglitazone Attenuates Oxidative Damage in Early Alzheimer's Disease by Binding mitoNEET. International Journal of Knowledge Discovery in Bioinformatics, 2015, 5, 24-45.	0.8	5
213	Meet the Editorial Board. Current Protein and Peptide Science, 2015, 16, 181-181.	0.7	0
214	Oxidative Damage is Correlated with Mitochondrial Autophagy. FASEB Journal, 2015, 29, 613.1.	0.2	0
215	Neuropathology of Alzheimer's Disease. , 2014, , 2014-2020.		3
216	Differential Network Analyses of Alzheimerâ€™s Disease Identify Early Events in Alzheimerâ€™s Disease Pathology. International Journal of Alzheimer's Disease, 2014, 2014, 1-18.	1.1	12

#	Article	IF	Citations
217	Cognitive decline due to excess synaptic Zn2+ signaling in the hippocampus. Frontiers in Aging Neuroscience, 2014, 6, 26.	1.7	38
218	Ethics Review as a Catalyst for Progress. Journal of Alzheimer's Disease, 2014, 40, 233-235.	1.2	2
219	Precision medicine using individualized biosimulations of drug dosing: Alzheimer's disease. , 2014, , .		6
220	Phosphorylation of tau protein at sites <scp>Ser</scp>^{396â€“404} is one of the earliest events in <scp>A</scp>lzheimer's disease and <scp>D</scp>own syndrome. Neuropathology and Applied Neurobiology, 2014, 40, 121-135.	1.8	207
221	Global warming and neurodegenerative disorders: speculations on their linkage. BioImpacts, 2014, 4, 167-170.	0.7	9
222	Dysregulation of leptin signaling in Alzheimer disease: evidence for neuronal leptin resistance. Journal of Neurochemistry, 2014, 128, 162-172.	2.1	110
223	The complexities of the pathologyâ€“pathogenesis relationship in Alzheimer disease. Biochemical Pharmacology, 2014, 88, 671-676.	2.0	77
224	Cognitive impairment in multiple system atrophy: A position statement by the neuropsychology task force of the MDS multiple system atrophy (MODIMSA) study group. Movement Disorders, 2014, 29, 857-867.	2.2	193
225	Oxidative stress and mitochondrial dysfunction in Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1240-1247.	1.8	982
226	Looking at Alzheimerâ€˜s disease from a different angle. Future Neurology, 2014, 9, 19-22.	0.9	0
227	Impact of RTN3 Deficiency on Expression of BACE1 and Amyloid Deposition. Journal of Neuroscience, 2014, 34, 13954-13962.	1.7	43
228	Scalable Collaborative Infrastructure for a Learning Healthcare System (SCILHS): Architecture. Journal of the American Medical Informatics Association: JAMIA, 2014, 21, 615-620.	2.2	76
229	Parallels Between Major Depressive Disorder and Alzheimerâ€™s Disease: Role of Oxidative Stress and Genetic Vulnerability. Cellular and Molecular Neurobiology, 2014, 34, 925-949.	1.7	82
230	Neuronal failure in Alzheimerâ€™s disease: a view through the oxidative stress looking-glass. Neuroscience Bulletin, 2014, 30, 243-252.	1.5	95
231	Pathogenesis of Alzheimerâ€™s Disease. , 2014, , 2327-2337.		1
232	Plaques and tangles: Birthmarks of the aging soul. Biochemical Pharmacology, 2014, 88, 423-425.	2.0	4
233	Amyloid Î²-Mediated Zn2+ Influx into Dentate Granule Cells Transiently Induces a Short-Term Cognitive Deficit. PLoS ONE, 2014, 9, e115923.	1.1	33
234	Low Plasma Leptin in Cognitively Impaired ADNI Subjects: Gender Differences and Diagnostic and Therapeutic Potential. Current Alzheimer Research, 2014, 11, 165-174.	0.7	54

#	Article	IF	Citations
235	Accumulation of Intraneuronal Amyloid-β is Common in Normal Brain. Current Alzheimer Research, 2014, 11, 317-324.	0.7	16
236	Islet Amyloid Polypeptide (IAPP): A Second Amyloid in Alzheimer's Disease. Current Alzheimer Research, 2014, 11, 928-940.	0.7	76
237	Alzheimer Disease Pathology in Middle Age Reveals a Spatial-Temporal Disconnect Between Amyloid-Î² and Phosphorylated Tau. The Open Neurology Journal, 2014, 8, 22-26.	0.4	10
238	Methemoglobinemiaâ€"A biomarker and a link to ferric iron accumulation in Alzheimerâ€™s disease. Advances in Bioscience and Biotechnology (Print), 2014, 05, 12-18.	0.3	5
239	Neuropsychiatric genetics in developing countries: Current challenges. World Journal of Psychiatry, 2014, 4, 69.	1.3	27
240	Lester (Skip) Binder (1949-2013): in the beginning was tau. Journal of Alzheimer's Disease, 2014, 40 Suppl 1, S5.	1.2	0
241	Modification of Amyloid-Î²1-42 Fibril Structure by Methionine-35 Oxidation. Journal of Alzheimer's Disease, 2013, 37, 9-18.	1.2	22
242	Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimerâ€™s and other neurodegenerative diseases. Translational Psychiatry, 2013, 3, e332-e332.	2.4	64
243	Antimicrobial peptide Î²-defensin-1 expression is upregulated in Alzheimerâ€™s brain. Journal of Neuroinflammation, 2013, 10, 127.	3.1	41
244	Oxidative stress in blood in Alzheimer's disease and mild cognitive impairment: A meta-analysis. Neurobiology of Disease, 2013, 59, 100-110.	2.1	260
245	Is exerciseâ€inâ€aâ€bottle likely to proffer new insights into Alzheimer's disease?. Journal of Neurochemistry, 2013, 127, 4-6.	2.1	2
246	Neurofilaments are the major neuronal target of hydroxynonenal-mediated protein cross-links. Free Radical Research, 2013, 47, 507-510.	1.5	13
247	The Structures of the E22Î" Mutant-Type Amyloid-Î² Alloforms and the Impact of E22Î" Mutation on the Structures of the Wild-Type Amyloid-Î² Alloforms. ACS Chemical Neuroscience, 2013, 4, 310-320.	1.7	38
248	Mitochondrial DNA Oxidative Damage and Repair in Aging and Alzheimer's Disease. Antioxidants and Redox Signaling, 2013, 18, 2444-2457.	2.5	138
249	Amyloid Î² peptides modify the expression of antioxidant repair enzymes and a potassium channel in the septohippocampal system. Neurobiology of Aging, 2013, 34, 2071-2076.	1.5	22
250	Tackling the Elusive Challenges Relevant to Conquering the 100-Plus Year Old Problem of Alzheimer's Disease. Current Alzheimer Research, 2013, 10, 108-116.	0.7	5
251	Proteolytic Cleavage of Polymeric Tau Protein by Caspase-3: Implications for Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2013, 72, 1145-1161.	0.9	43
252	Phosphorylation of Tau Protein as the Link between Oxidative Stress, Mitochondrial Dysfunction, and Connectivity Failure: Implications for Alzheimerâ€™s Disease. Oxidative Medicine and Cellular Longevity, 2013, 2013, 1-6.	1.9	108

#	Article	IF	Citations
253	Nutrients and Food Constituents in Cognitive Decline and Neurodegenerative Disease. , 2013, , 373-390.		0
254	Molecular Pathology of Alzheimer's Disease. Colloquium Series on Neurobiology of Alzheimer S Disease, 2013, 1, 1-91.	0.0	4
255	A Low-Molecular-Weight Ferroxidase Is Increased in the CSF of sCJD Cases: CSF Ferroxidase and Transferrin as Diagnostic Biomarkers for sCJD. Antioxidants and Redox Signaling, 2013, 19, 1662-1675.	2.5	22
256	Foreword (The Largest Unmet Market: Chronic Diseases of Aging). Mini-Reviews in Medicinal Chemistry, 2013, 13, 1-1.	1.1	6
257	DNA Damage in Alzheimer Disease Lymphocytes and Its Relation to Premature Centromere Division. Neurodegenerative Diseases, 2013, 12, 156-163.	0.8	19
258	Deconstructing Mitochondrial Dysfunction in Alzheimer Disease. Oxidative Medicine and Cellular Longevity, 2013, 2013, 1-13.	1.9	98
259	Are Alzheimer's Disease and Aging Evolutionary?. Journal of Alzheimer's Disease, 2013, 35, 637-637.	1.2	1
260	Larry Sparks: Innovator and Iconoclast. Journal of Alzheimer's Disease, 2013, 37, 1-1.	1.2	0
261	Apolipoprotein E4 Prevents Growth of Malaria at the Intraerythrocyte Stage: Implications For Diff erences in Racial Susceptibility to Alzheimerâ€™s Disease. Journal of Health Care for the Poor and Underserved, 2013, 24, 70-78.	0.4	27
262	Mitochondrial Abnormalities in a Streptozotocin-Induced Rat Model of Sporadic Alzheimer's Disease. Current Alzheimer Research, 2013, 10, 406-419.	0.7	106
263	Tryptamine Induces Axonopathy and Mitochondriopathy Mimicking Neurodegenerative Diseases via Tryptophanyl-tRNA Deficiency. Current Alzheimer Research, 2013, 10, 987-1004.	0.7	30
264	Fractal Analysis of Epithelial-Connective Tissue Interface in Basal Cell Carcinoma of the Skin. Current Bioinformatics, 2013, 8, 357-361.	0.7	6
265	Tackling the Elusive Challenges Relevant to Conquering the 100-Plus Year Old Problem of Alzheimerâ€™s Disease. Current Alzheimer Research, 2013, 10, 108-116.	0.7	5
266	Cloningâ€™s Promise. Cloning & Transgenesis, 2013, 02, .	0.1	0
267	Fractal dimension of bone texture in radiographs correlates to ultrasound broadband attenuation T-score. Clinical and Experimental Rheumatology, 2013, 31, 389-93.	0.4	2
268	The largest unmet market: chronic diseases of aging. Mini-Reviews in Medicinal Chemistry, 2013, 13, 1.	1.1	7
269	Alzheimer's Disease and Vascular Deficiency: Lessons from Imaging Studies and Down Syndrome. Current Gerontology and Geriatrics Research, 2012, 2012, 1-5.	1.6	5
270	LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Human Molecular Genetics, 2012, 21, 1931-1944.	1.4	356

#	Article	IF	Citations
271	Isotyping the Human TOMM40 Variable-Length Polymorphism by Gene Amplification and Restriction Digest. Current Alzheimer Research, 2012, 9, 1168-1173.	0.7	0
272	Editorial [Special Issue in Honor of the 70th Birthday of Dr. Atta-ur-Rahman, FRS]. Mini-Reviews in Medicinal Chemistry, 2012, 12, i-i.	1.1	0
273	Cellular prion protein is essential for oligomeric amyloid-Â-induced neuronal cell death. Human Molecular Genetics, 2012, 21, 1138-1144.	1.4	105
274	Molecular neuropathogenesis of Alzheimerâ€™s disease: an interaction model stressing the central role of oxidative stress. Future Neurology, 2012, 7, 287-305.	0.9	13
275	Iron chelation and nanoparticle target delivery in the development of new multifunctional disease-modifying drugs for Alzheimerâ€™s disease. Therapeutic Delivery, 2012, 3, 571-574.	1.2	2
276	Editorial (A New Era for Medicinal Chemistry). Mini-Reviews in Medicinal Chemistry, 2012, 12, 1-1.	1.1	9
277	Neuroinflammation, Hyperphosphorylated Tau, Diffuse Amyloid Plaques, and Down-Regulation of the Cellular Prion Protein in Air Pollution Exposed Children and Young Adults. Journal of Alzheimer's Disease, 2012, 28, 93-107.	1.2	234
278	The Earliest Stage of Cognitive Impairment in Transition From Normal Aging to Alzheimer Disease Is Marked by Prominent RNA Oxidation in Vulnerable Neurons. Journal of Neuropathology and Experimental Neurology, 2012, 71, 233-241.	0.9	100
279	Untangling the Vascular Web from Alzheimer Disease and Oxidative Stress. Canadian Journal of Neurological Sciences, 2012, 39, 4-4.	0.3	6
280	The impairment of insulin signaling in Alzheimer's disease. IUBMB Life, 2012, 64, 951-957.	1.5	56
281	Pathogenesis and Disease-modifying Therapy in Alzheimer's Disease: The Flat Line of Progress. Archives of Medical Research, 2012, 43, 694-698.	1.5	85
282	AGEs/RAGE complex upregulates BACE1 via NF-ÎºB pathway activation. Neurobiology of Aging, 2012, 33, 196.e13-196.e27.	1.5	123
283	Î²â€Amyloid 1â€42 induces physiological transcriptional regulation of BACE1. Journal of Neurochemistry, 2012, 122, 1023-1031.	2.1	22
284	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	4.3	3,122
285	Nuclear and mitochondrial DNA oxidation in Alzheimer's disease. Free Radical Research, 2012, 46, 565-576.	1.5	46
286	Mark Smith: Pioneer of Alzheimer Disease Research. Neurotoxicity Research, 2012, 22, 181-181.	1.3	0
287	Structures and free energy landscapes of aqueous zinc(II)-bound amyloid-Î²(1â€“40) and zinc(II)-bound amyloid-Î²(1â€“42) with dynamics. Journal of Biological Inorganic Chemistry, 2012, 17, 927-938.	1.1	40
288	Amyloid Beta and Tau Proteins as Therapeutic Targets for Alzheimerâ€™s Disease Treatment: Rethinking the Current Strategy. International Journal of Alzheimer's Disease, 2012, 2012, 1-7.	1.1	45

#	Article	IF	Citations
289	The Contribution of the Amyloid Hypothesis to the Understanding of Alzheimer's Disease: A Critical Overview. International Journal of Alzheimer's Disease, 2012, 2012, 1-2.	1.1	1
290	Glycogen Synthase Kinase 3: A Point of Integration in Alzheimer's Disease and a Therapeutic Target?. International Journal of Alzheimer's Disease, 2012, 2012, 1-4.	1.1	16
291	Alzheimer's Disease: Advances for a New Century. Journal of Alzheimer's Disease, 2012, 33, S1-S1.	1.2	2
292	DoÎ²-Defensins and Other Antimicrobial Peptides Play a Role in Neuroimmune Function and Neurodegeneration?. Scientific World Journal, The, 2012, 2012, 1-11.	0.8	37
293	Journal of Huntington's Disease â€“ The Family Gets Bigger. Journal of Alzheimer's Disease, 2012, 30, 735-735.	1.2	0
294	Nanoparticle Delivery of Transition-Metal Chelators to the Brain: Oxidative Stress will Never See it Coming!. CNS and Neurological Disorders - Drug Targets, 2012, 11, 81-85.	0.8	35
295	Inge Grundke-Iqbal: A Legacy of Tau in the Etiology of Alzheimer Disease (1937â€“2012). Journal of Alzheimer's Disease, 2012, 33, 1-2.	1.2	1
296	Abnormal Mitochondrial Dynamics in the Pathogenesis of Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 33, S253-S262.	1.2	166
297	Oxidative Damage to RNA in Aging and Neurodegenerative Disorders. Neurotoxicity Research, 2012, 22, 231-248.	1.3	162
298	Mitochondrial Importance in Alzheimerâ€™s, Huntingtonâ€™s and Parkinsonâ€™s Diseases. Advances in Experimental Medicine and Biology, 2012, 724, 205-221.	0.8	57
299	The role of iron as a mediator of oxidative stress in Alzheimer disease. BioFactors, 2012, 38, 133-138.	2.6	64
300	Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimerâ€™s disease. Journal of Neurochemistry, 2012, 120, 419-429.	2.1	422
301	Mark A. Smith: neurocytochemistry innovator. Journal of Neurochemistry, 2012, 120, 1139-1140.	2.1	0
302	Hydroxynonenal-generated crosslinking fluorophore accumulation in Alzheimer disease reveals a dichotomy of protein turnover. Free Radical Biology and Medicine, 2012, 52, 699-704.	1.3	38
303	Editorial - Chronic or Late Lyme Neuroborreliosis: Present and Future. The Open Neurology Journal, 2012, 6, 78-78.	0.4	2
304	A Pleotrophic Age for Alzheimer and Parkinson disease. , 2012, 02, .		0
305	Pharmaceutical Regulation: Crossroad of Opportunity as the Distinction between Food and Drugs Blurs. Pharmaceutical Regulatory Affairs: Open Access, 2012, 01, .	0.2	0
306	Therapeutic Opportunities in Alzheimer Disease: Current Concepts. , 2012, , 767-788.		0

#	Article	IF	Citations
307	R-_-Lipoic Acid as a Potent Agent of Mitochondrial Protectionin Alzheimerâ€™s Disease. Oxidative Stress and Disease, 2012, , 455-467.	0.3	0
308	In Vivo and In Silico Evidence: Hippocampal Cholesterol Metabolism Decreases with Aging and Increases with Alzheimers Disease -- Modeling Brain Aging and Disease. , 2011, , .		3
309	Modeling cholesterol metabolism by gene expression profiling in the hippocampus. Molecular BioSystems, 2011, 7, 1891.	2.9	11
310	Insulin-resistant brain state: The culprit in sporadic Alzheimer's disease?. Ageing Research Reviews, 2011, 10, 264-273.	5.0	195
311	Frontiers in Alzheimerâ€™s disease therapeutics. Therapeutic Advances in Chronic Disease, 2011, 2, 9-23.	1.1	26
312	Role of metal dyshomeostasis in Alzheimer's disease. Metallomics, 2011, 3, 267.	1.0	267
313	Mark A. Smith: Scholar and Innovator. European Journal of Histochemistry, 2011, 55, 2.	0.6	1
314	Imaging the Alzheimer Brain. Journal of Alzheimer's Disease, 2011, 26, 1-27.	1.2	41
315	Mark Anthony Smith (1965â€“2010): Visionary, Alzheimer Researcher, and Editor-in-Chief of the Journal of Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 24, 1-2.	1.2	7
316	Journal of Parkinson's Disease â€“ Birth of JAD's New Sister. Journal of Alzheimer's Disease, 2011, 25, 1-1.	1.2	7
317	Drug Discovery for Neurodegenerative Diseases: Challenges and Novel Biochemical Targets. Journal of Alzheimer's Disease, 2011, 24, 1-2.	1.2	13
318	Alzheimerâ€™s disease therapy: a moving target. Therapy: Open Access in Clinical Medicine, 2011, 8, 457-458.	0.2	0
319	A Novel Perspective on Tau in Alzheimers Disease. Current Alzheimer Research, 2011, 8, 639-642.	0.7	24
320	Mark A. Smith, PhD: Renegade Scientist and Visionary. Journal of Neuropathology and Experimental Neurology, 2011, 70, 495-497.	0.9	0
321	The Cell Cycle Regulator Phosphorylated Retinoblastoma Protein Is Associated With Tau Pathology in Several Tauopathies. Journal of Neuropathology and Experimental Neurology, 2011, 70, 578-587.	0.9	32
322	The Mitochondrial Dynamics of Alzheimers Disease and Parkinsons Disease Offer Important Opportunities for Therapeutic Intervention. Current Pharmaceutical Design, 2011, 17, 3374-3380.	0.9	30
323	Mark A. Smith: The Scientist, the Man. International Journal of Experimental Pathology, 2011, 92, 297-298.	0.6	1
324	DLP1â€dependent mitochondrial fragmentation mediates 1â€methylâ€4â€phenylpyridinium toxicity in neurons: implications for Parkinsonâ€™s disease. Aging Cell, 2011, 10, 807-823.	3.0	113

#	Article	IF	Citations
325	The origin of oxidative stress in neurodegenerative disease: Mark Anthony Smith 1965â€“2010. Free Radical Biology and Medicine, 2011, 51, 248-249.	1.3	3
326	CD3 in Lewy pathology: does the abnormal recall of neurodevelopmental processes underlie Parkinsonâ€™s disease. Journal of Neural Transmission, 2011, 118, 23-26.	1.4	13
327	Intrahippocampal Amyloid-β (1-40) Injections Injure Medial Septal Neurons in Rats. Current Alzheimer Research, 2011, 8, 832-840.	0.7	20
328	Amyloid-Î² peptide structure in aqueous solution varies with fragment size. Journal of Chemical Physics, 2011, 135, 205101.	1.2	47
329	Neurodegenerative processes in Alzheimerâ€™s disease: an overview of pathogenesis with strategic biomarker potential. Future Neurology, 2011, 6, 173-185.	0.9	0
330	A novel origin for granulovacuolar degeneration in aging and Alzheimer's disease: parallels to stress granules. Laboratory Investigation, 2011, 91, 1777-1786.	1.7	44
331	The concept of redox balance in Alzheimer's disease: Mark Anthony Smith 1965â€“2010. Redox Report, 2011, 16, 47-48.	1.4	0
332	Oxidative Stress in Alzheimerâ€™s Disease: A Critical Appraisal of the Causes and the Consequences. , 2011, , 211-220.		2
333	New Insights into the Mechanisms of Mitochondrial Preconditioning-Triggered Neuroprotection. Current Pharmaceutical Design, 2011, 17, 3381-3389.	0.9	28
334	Neurofilamentopathy in Neurodegenerative Diseases. The Open Neurology Journal, 2011, 5, 58-62.	0.4	56
335	Transcriptome-To-Metabolomeâ„¢ Biosimulation Reveals Human Hippocampal Hypometabolism with Age and Alzheimerâ€™s Disease. International Journal of Knowledge Discovery in Bioinformatics, 2011, 2, 1-18.	0.8	3
336	Oxidative Stress and Alzheimer Disease: Mechanisms and Therapeutic Opportunities. Advances in Neurobiology, 2011, , 607-631.	1.3	0
337	Association of Mitochondrial Signaling in Alzheimerâ€™s Disease and Hypoxia. , 2011, , 50-61.		0
338	Launch of â€˜Atlas Journal of Medical and Biological Sciencesâ€™. Atlas Journal of Medical and Biological Sciences, 2011, `, 1-1.	0.3	1
339	Pathological phenotype in familial neurodegenerative disease: implications for families and therapeutic constructs. Therapy: Open Access in Clinical Medicine, 2011, 8, 475-479.	0.2	0
340	Increased Iron and Free Radical Generation in Preclinical Alzheimer Disease and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2010, 19, 363-372.	1.2	357
341	Elevation of Î²-Amyloid 1-42 Autoantibodies in the Blood of Amnestic Patients With Mild Cognitive Impairment. Archives of Neurology, 2010, 67, 867-72.	4.9	30
342	Antioxidant approaches for the treatment of Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2010, 10, 1201-1208.	1.4	103

#	Article	IF	Citations
343	Chapter 19. Targeting Oxidative Mechanisms in Alzheimer Disease. RSC Drug Discovery Series, 2010, , 97-107.	0.2	0
344	Abnormal Mitochondrial Dynamicsâ€"A Novel Therapeutic Target for Alzheimer's Disease?. Molecular Neurobiology, 2010, 41, 87-96.	1.9	75
345	Intraneuronal amyloid Î² accumulation and oxidative damage to nucleic acids in Alzheimer disease. Neurobiology of Disease, 2010, 37, 731-737.	2.1	88
346	Dissociated amyloid-Î² antibody levels as a serum biomarker for the progression of Alzheimerâ€™s disease: A population-based study. Experimental Gerontology, 2010, 45, 47-52.	1.2	31
347	Cholesterol homeostasis markers are localized to mouse hippocampal pyramidal and granule layers. Hippocampus, 2010, 20, 902-905.	0.9	30
348	Variably proteaseâ€sensitive prionopathy: A new sporadic disease of the prion protein. Annals of Neurology, 2010, 68, 162-172.	2.8	203
349	Paraffin-embedded tissue (PET) blot method: Application to Alzheimer disease. Journal of Neuroscience Methods, 2010, 190, 244-247.	1.3	6
350	Divalent metal transporter, iron, and Parkinson's disease: A pathological relationship. Cell Research, 2010, 20, 397-399.	5.7	13
351	Widespread distribution of reticulon-3 in various neurodegenerative diseases. Neuropathology, 2010, 30, 574-579.	0.7	18
352	William R. Markesbery, M.D.: A Tribute. Journal of Alzheimer's Disease, 2010, 20, 1-1.	1.2	21
353	Mitochondria and Neurodegenerative Diseases. Journal of Alzheimer's Disease, 2010, 20, S253-S253.	1.2	2
354	Mitochondrial preconditioning: a potential neuroprotective strategy. Frontiers in Aging Neuroscience, 2010, 2, .	1.7	29
355	A Synergistic Dysfunction of Mitochondrial Fission/Fusion Dynamics and Mitophagy in Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 20, S401-S412.	1.2	141
356	Prospects on the Origin of Alzheimer's disease. Journal of Alzheimer's Disease, 2010, 20, 669-672.	1.2	3
357	Mitochondria: The Missing Link Between Preconditioning and Neuroprotection. Journal of Alzheimer's Disease, 2010, 20, S475-S485.	1.2	46
358	Oxidative Stress and Neurodegeneration: An Inevitable Consequence of Aging? Implications for Therapy. , 2010, , 305-323.		5
359	Potential Role of Iron in a Mediterranean-style Diet. Archives of Neurology, 2010, 67, 1286.	4.9	3
360	Upregulation of Presenilin 1 in Brains of Sporadic, Late-Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 22, 771-775.	1.2	19

#	Article	IF	Citations
361	NMR Studies of Zinc, Copper, and Iron Binding to Histidine, the Principal Metal Ion Complexing Site of Amyloid-Î² Peptide. Journal of Alzheimer's Disease, 2010, 20, 57-66.	1.2	95
362	Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimer's disease. Redox Report, 2010, 15, 161-168.	1.4	103
363	Amyloid-Î²-Derived Diffusible Ligands Cause Impaired Axonal Transport of Mitochondria in Neurons. Neurodegenerative Diseases, 2010, 7, 56-59.	0.8	120
364	Specific reaction of Met 35 in amyloid beta peptide with hypochlorous acid. Free Radical Research, 2010, 44, 734-741.	1.5	1
365	Biomarkers in Alzheimerâ€™s disease: past, present and future. Biomarkers in Medicine, 2010, 4, 15-26.	0.6	57
366	Detection and Localization of Markers of Oxidative Stress by In Situ Methods: Application in the Study of Alzheimer Disease. Methods in Molecular Biology, 2010, 610, 419-434.	0.4	55
367	Chronic oxidative stress causes increased tau phosphorylation in M17 neuroblastoma cells. Neuroscience Letters, 2010, 468, 267-271.	1.0	141
368	Abnormal mitochondrial dynamics and neurodegenerative diseases. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 135-142.	1.8	229
369	Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 2-10.	1.8	587
370	Mitochondria: A therapeutic target in neurodegeneration. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 212-220.	1.8	244
371	Mathematical modeling of microtubule dynamics: Insights into physiology and disease. Progress in Neurobiology, 2010, 92, 478-483.	2.8	19
372	Oxidative stress in Alzheimer disease: A possibility for prevention. Neuropharmacology, 2010, 59, 290-294.	2.0	431
373	Signaling effect of amyloid-Î²42 on the processing of AÎ²PP. Experimental Neurology, 2010, 221, 18-25.	2.0	51
374	Memantine. American Journal of Pathology, 2010, 176, 540-541.	1.9	4
375	Nanoparticle and Iron Chelators as a Potential Novel Alzheimer Therapy. Methods in Molecular Biology, 2010, 610, 123-144.	0.4	87
376	Autophagy in Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2010, 10, 1209-1218.	1.4	51
377	Causes versus effects: the increasing complexities of Alzheimerâ€™s disease pathogenesis. Expert Review of Neurotherapeutics, 2010, 10, 683-691.	1.4	61
378	Mitochondrial Dynamics in AlzheimerÊ¼s Disease. Drugs and Aging, 2010, 27, 181-192.	1.3	86

#	Article	IF	Citations
379	A Novel Endogenous Indole Protects Rodent Mitochondria and Extends Rotifer Lifespan. PLoS ONE, 2010, 5, e10206.	1.1	38
380	Alzheimer's disease: diverse aspects of mitochondrial malfunctioning. International Journal of Clinical and Experimental Pathology, 2010, 3, 570-81.	0.5	75
381	Novel therapeutics for Alzheimer's disease: an update. Current Opinion in Drug Discovery & Development, 2010, 13, 235-46.	1.9	26
382	Oxidative Stress and its Implications for Future Treatments and Management of Alzheimer Disease. International Journal of Biomedical Science, 2010, 6, 225-227.	0.5	29
383	Insulin and Insulin-Sensitizing Drugs in Neurodegeneration: Mitochondria as Therapeutic Targets. Pharmaceuticals, 2009, 2, 250-286.	1.7	9
384	Impaired Balance of Mitochondrial Fission and Fusion in Alzheimer's Disease. Journal of Neuroscience, 2009, 29, 9090-9103.	1.7	1,003
385	Molecular Pathogenesis of Alzheimerâ€™s Disease: Reductionist versus Expansionist Approaches. International Journal of Molecular Sciences, 2009, 10, 1386-1406.	1.8	43
386	Is Alzheimers Disease a Myth? When is Disease a Disease?. Current Alzheimer Research, 2009, 6, 82-82.	0.7	0
387	Natural Oxidant Balance in Parkinson Disease. Archives of Neurology, 2009, 66, 1445.	4.9	4
388	Neuronal mitochondrial amelioration by feeding acetylâ€Łâ€carnitine and lipoic acid to aged rats. Journal of Cellular and Molecular Medicine, 2009, 13, 320-333.	1.6	105
389	Insights into cerebrovascular complications and Alzheimer disease through the selective loss of GRK2 regulation. Journal of Cellular and Molecular Medicine, 2009, 13, 853-865.	1.6	17
390	The effect of mGluR2 activation on signal transduction pathways and neuronal cell survival. Brain Research, 2009, 1249, 244-250.	1.1	37
391	Altered redox balance in disease: Can we change the new equilibria?. Annals of Neurology, 2009, 65, 121-123.	2.8	7
392	The Neuroscience Peer Review Consortium. Journal of Comparative Neurology, 2009, 513, 333-334.	0.9	1
393	Neuroprotective effect of cocoa flavonids on in vitro oxidative stress. European Journal of Nutrition, 2009, 48, 54-61.	1.8	57
394	RNA oxidation in Alzheimer disease and related neurodegenerative disorders. Acta Neuropathologica, 2009, 118, 151-166.	3.9	134
395	Role of mitochondrial-mediated signaling pathways in Alzheimer disease and hypoxia. Journal of Bioenergetics and Biomembranes, 2009, 41, 433-440.	1.0	63
396	Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson's disease. Molecular Neurodegeneration, 2009, 4, 32.	4.4	34

#	Article	IF	Citations
397	The upâ€regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1Î±. Journal of Neurochemistry, 2009, 108, 1045-1056.	2.1	217
398	The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimerâ€™s disease. Journal of Neurochemistry, 2009, 109, 153-159.	2.1	245
399	The essential role of ERK in 4â€oxoâ€2â€nonenalâ€mediated cytotoxicity in SHâ€SY5Y human neuroblastoma cells. Journal of Neurochemistry, 2009, 108, 1434-1441.	2.1	13
400	Tau â€“ an inhibitor of deacetylase HDAC6 function. Journal of Neurochemistry, 2009, 109, 1756-1766.	2.1	153
401	Insulin is a Two-Edged Knife on the Brain. Journal of Alzheimer's Disease, 2009, 18, 483-507.	1.2	124
402	A novel approach to the identification and quantitative elemental analysis of amyloid depositsâ€”Insights into the pathology of Alzheimerâ€™s disease. Biochemical and Biophysical Research Communications, 2009, 382, 91-95.	1.0	96
403	Getting the iron out: Phlebotomy for Alzheimerâ€™s disease?. Medical Hypotheses, 2009, 72, 504-509.	0.8	34
404	Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's disease. Neurochemistry International, 2009, 54, 84-88.	1.9	125
405	Nanoparticleâ€“chelator conjugates as inhibitors of amyloid-Î² aggregation and neurotoxicity: A novel therapeutic approach for Alzheimer disease. Neuroscience Letters, 2009, 455, 187-190.	1.0	138
406	Down-regulation of aminolevulinate synthase, the rate-limiting enzyme for heme biosynthesis in Alzheimer's disease. Neuroscience Letters, 2009, 460, 180-184.	1.0	18
407	Heme-a, the heme prosthetic group of cytochrome c oxidase, is increased in Alzheimer's disease. Neuroscience Letters, 2009, 461, 302-305.	1.0	8
408	Development of iron chelatorâ€“nanoparticle conjugates as potential therapeutic agents for Alzheimer disease. Progress in Brain Research, 2009, 180, 97-108.	0.9	19
409	Neurofibrillary Tangle Formation as a Protective Response to Oxidative Stress in Alzheimerâ€™s Disease. , 2009, , 103-113.		3
410	Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer's disease. Free Radical Research, 2009, 43, 156-164.	1.5	65
411	All-transretinoic acid as a novel therapeutic strategy for Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2009, 9, 1615-1621.	1.4	104
412	Leptin: A Novel Therapeutic Strategy for Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 16, 731-740.	1.2	114
413	The Neuroscience Peer Review Consortium. European Psychiatry, 2009, 24, 69-70.	0.1	0
414	The Neuronal Expression of MYC Causes a Neurodegenerative Phenotype in a Novel Transgenic Mouse. American Journal of Pathology, 2009, 174, 891-897.	1.9	82

#	Article	IF	Citations
415	Mitochondrial Drugs for Alzheimer Disease. Pharmaceuticals, 2009, 2, 287-298.	1.7	15
416	Oxidative Stress in Diabetes and Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 16, 763-774.	1.2	244
417	Food Antioxidants and Alzheimerâ€™s Disease. Oxidative Stress and Disease, 2009, , .	0.3	0
418	Reexamining Alzheimer's Disease: Evidence for a Protective Role for Amyloid-Î² Protein Precursor and Amyloid-Î². Journal of Alzheimer's Disease, 2009, 18, 447-452.	1.2	139
419	2009 Award Recipients-Peter C. Burger, MD, Pierluigi Gambetti, MD, and Nicholas K. Gonatas, MD. Journal of Neuropathology and Experimental Neurology, 2009, 68, 1244-1246.	0.9	0
420	Metal Chelators Coupled with Nanoparticles as Potential Therapeutic Agents for Alzheimer's Disease. Journal of Nanoneuroscience, 2009, 1, 42-55.	0.5	34
421	Evidence for Oxidative Damage in the Autistic Brain. , 2009, , 35-46.		4
422	Evidence for the progression through S-phase in the ectopic cell cycle re-entry of neurons in Alzheimer disease. Aging, 2009, 1, 382-388.	1.4	73
423	Oxidative Stress in Parkinson`s Disease. The Open Pathology Journal, 2009, 3, 38-42.	1.0	6
424	Cellular Respiration and Tumor Suppressor Genes. , 2009, , 131-144.		0
425	Oxidative Stress Associated Signal Transduction Cascades in Alzheimer Disease. Contemporary Clinical Neuroscience, 2009, , 121-136.	0.3	0
426	Alzheimer Disease: Oxidative Stress and Compensatory Responses. , 2009, , 109-120.		0
427	Neuronal Cytoskeleton Regulation and Neurodegeneration. , 2009, , 63-78.		1
428	Treatment advances in Alzheimer's disease based on the oxidative stress model. F1000 Medicine Reports, 2009, 1, .	2.9	2
429	Evidence for the novel expression of human kallikrein-related peptidase 3, prostate-specific antigen, in the brain. International Journal of Clinical and Experimental Pathology, 2009, 2, 267-74.	0.5	6
430	Iron: A Pathological Mediator of Alzheimer Disease?. Agro Food Industry Hi-tech, 2009, 19, 33-36.	1.0	7
431	Oxidative stress activates a positive feedback between the Î³â€•and Î²â€‘secretase cleavages of the Î²â€‘amyloid precursor protein. Journal of Neurochemistry, 2008, 104, 683-695.	2.1	287
432	Evidence of DNA damage in Alzheimer disease: phosphorylation of histone H2AX in astrocytes. Age, 2008, 30, 209-215.	3.0	133

#	Article	IF	Citations
433	Expression of CD74 is increased in neurofibrillary tangles in Alzheimer's disease. Molecular Neurodegeneration, 2008, 3, 13.	4.4	64
434	Activation of MKK6, an upstream activator of p38, in Alzheimer's disease. Journal of Neurochemistry, 2008, 79, 311-318.	2.1	141
435	Physiological regulation of tau phosphorylation during hibernation. Journal of Neurochemistry, 2008, 105, 2098-2108.	2.1	79
436	Antigenâ€“antibody dissociation in Alzheimer disease: a novel approach to diagnosis. Journal of Neurochemistry, 2008, 106, 1350-1356.	2.1	47
437	Redox active iron accumulation in aceruloplasminemia. Neuropathology, 2008, 28, 466-471.	0.7	46
438	Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimerâ€™s disease. International Journal of Experimental Pathology, 2008, 89, 81-90.	0.6	113
439	Neuronal binucleation in Alzheimer disease hippocampus. Neuropathology and Applied Neurobiology, 2008, 34, 457-465.	1.8	51
440	Nucleic acid oxidation in Alzheimer disease. Free Radical Biology and Medicine, 2008, 44, 1493-1505.	1.3	188
441	Current approaches in the treatment of Alzheimer's disease. Biomedicine and Pharmacotherapy, 2008, 62, 199-207.	2.5	139
442	DOES THE OXIDATIVE STRESS AND CEREBRAL ATHEROSCLEROSIS INITIATE BRAIN HYPOPERFUSION AND THE DEVELOPMENT OF ALZHEIMER DISEASE?. Atherosclerosis Supplements, 2008, 9, 154.	1.2	1
443	Oxidative Stress and Neurotoxicity. Chemical Research in Toxicology, 2008, 21, 172-188.	1.7	707
444	Alzheimer Disease Pathology As a Host Response. Journal of Neuropathology and Experimental Neurology, 2008, 67, 523-531.	0.9	150
445	Leucine-Rich Repeat Kinase 2 Colocalizes with Î±-Synuclein in Parkinsonâ€™s Disease, but Not Tau-Containing Deposits in Tauopathies. Neurodegenerative Diseases, 2008, 5, 222-224.	0.8	29
446	A New Model of Oxidative Stress in Rat Pups. Neonatology, 2008, 94, 293-299.	0.9	8
447	Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy, 2008, 4, 151-175.	4.3	2,064
448	Antibodies to Potato Virus Y Bind the Amyloid Î² Peptide. Journal of Biological Chemistry, 2008, 283, 22550-22556.	1.6	24
449	Oxidative Stress Signaling in Alzheimers Disease. Current Alzheimer Research, 2008, 5, 525-532.	0.7	250
450	Stem cell niches as clinical targets: the future of anti-ischemic therapy?. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 590-591.	3.3	9

#	Article	IF	Citations
451	Menopause, Estrogen, and Gonadotropins in Alzheimer's Disease. Advances in Clinical Chemistry, 2008, 45, 139-153.	1.8	10
452	Cerebrotendinous xanthomatosis: a critical update. Future Neurology, 2008, 3, 491-501.	0.9	2
453	Nonestrogen-based hormonal therapies for Alzheimerâ€™s disease. Future Neurology, 2008, 3, 399-407.	0.9	0
454	From Aging to Alzheimer's Disease: Unveiling â€œThe Switchâ€•with the Senescence-Accelerated Mouse Model (SAMP8). Journal of Alzheimer's Disease, 2008, 15, 615-624.	1.2	177
455	Three-Dimensional Tomographic Imaging and Characterization of Iron Compounds within Alzheimer's Plaque Core Material. Journal of Alzheimer's Disease, 2008, 14, 235-245.	1.2	136
456	Alzheimer Disease and the Role of Free Radicals in the Pathogenesis of the Disease. CNS and Neurological Disorders - Drug Targets, 2008, 7, 3-10.	0.8	136
457	Phosphorylated Tau: Toxic, Protective, or None of the Above. Journal of Alzheimer's Disease, 2008, 14, 377-383.	1.2	80
458	Alzheimer's Disease: Cerebrovascular Dysfunction, Oxidative stress, and Advanced Clinical Therapies. Journal of Alzheimer's Disease, 2008, 15, 199-210.	1.2	75
459	Sublethal RNA Oxidation as a Mechanism for Neurodegenerative Disease. International Journal of Molecular Sciences, 2008, 9, 789-806.	1.8	35
460	Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels: Implication in the pathogenesis of Alzheimer’s disease. Vascular Health and Risk Management, 2008, Volume 4, 721-730.	1.0	53
461	Transgenic Mouse Models of Alzheimer's Disease. Frontiers in Neuroscience, 2008, , 1-18.	0.0	4
462	Antioxidant Therapy in Alzheimers Disease: Theory and Practice. Mini-Reviews in Medicinal Chemistry, 2008, 8, 1395-1406.	1.1	129
463	The Autistic Phenotype Exhibits a Remarkably Localized Modification of Brain Protein by Products of Free Radical-Induced Lipid Oxidation. American Journal of Biochemistry and Biotechnology, 2008, 4, 61-72.	0.1	47
464	The primary pathogenetic role of vascular hypoperfusion, mitochondria failure and oxidative stress in aging and Alzheimer disease. FASEB Journal, 2008, 22, 167.3.	0.2	0
465	Antibodyâ€Antigen Dissociation: A Novel Diagnostic Tool in Alzheimer Disease. FASEB Journal, 2008, 22, 167.10.	0.2	0
466	Neurodegenerative Phenotypes Induced by MYCâ€Driven Neuronal Cell Cycle Reâ€entry: Relevance to Alzheimer Disease. FASEB Journal, 2008, 22, 167.6.	0.2	0
467	Role of Oxidative Insult and Neuronal Survival in Alzheimerâ€™s and Parkinsonâ€™s Diseases. , 2008, , 133-148.		0
468	Two Hits and Youâ€™re Out? A Novel Mechanistic Hypothesis of Alzheimer Disease. , 2008, , 191-204.		2

#	Article	IF	Citations
469	Pathology's new role: defining disease process and protective responses. International Journal of Clinical and Experimental Pathology, 2008, 1, 1-4.	0.5	2
470	Retinoblastoma protein phosphorylation at multiple sites is associated with neurofibrillary pathology in Alzheimer disease. International Journal of Clinical and Experimental Pathology, 2008, 1, 134-46.	0.5	24
471	Copper Induces Apoptosis of Neuroblastoma Cells Via Post-translational Regulation of the Expression of Bcl-2-family Proteins and the tx Mouse is a Better Model of Hepatic than Brain Cu Toxicity. International Journal of Clinical and Experimental Medicine, 2008, 1, 76-88.	1.3	11
472	Oxidative Stress Is an Early Event in Hydrostatic Pressureâ€“Induced Retinal Ganglion Cell Damage. , 2007, 48, 4580.		147
473	Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees?. Expert Review of Neurotherapeutics, 2007, 7, 473-485.	1.4	41
474	Increased Expression of the Remodeling- and Tumorigenic-Associated Factor Osteopontin in Pyramidal Neurons of the Alzheimers Disease Brain. Current Alzheimer Research, 2007, 4, 67-72.	0.7	62
475	Prevention and Treatment of Alzheimer Disease and Aging: Antioxidants. Mini-Reviews in Medicinal Chemistry, 2007, 7, 171-180.	1.1	59
476	Iron homeostasis is maintained in the brain, but not the liver, following mild hypoxia. Redox Report, 2007, 12, 257-266.	1.4	8
477	Cerebrotendinous xanthomatosis: case report with evidence of oxidative stress. Redox Report, 2007, 12, 119-124.	1.4	11
478	Amyloid-Î² in Alzheimer Disease: The Null versus the Alternate Hypotheses. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 823-829.	1.3	144
479	The Contribution of Luteinizing Hormone to Alzheimer Disease Pathogenesis. Clinical Medicine and Research, 2007, 5, 177-183.	0.4	39
480	Increased Autophagic Degradation of Mitochondria in Alzheimer Disease. Autophagy, 2007, 3, 614-615.	4.3	147
481	Prospects for Antioxidant Therapy in Mild Cognitive Impairment and Alzheimer's Disease. , 2007, , 451-466.		2
482	Signal Transduction Cascades Associated with Oxidative Stress in Alzheimer's Disease. Journal of Alzheimer's Disease, 2007, 11, 143-152.	1.2	95
483	Autophagocytosis of Mitochondria Is Prominent in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2007, 66, 525-532.	0.9	138
484	Evidence for the Role of Luteinizing Hormone in Alzheimer Disease. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2007, 7, 300-303.	0.6	19
485	Neuronal Death and Survival Under Oxidative Stress in Alzheimer and Parkinson Diseases. CNS and Neurological Disorders - Drug Targets, 2007, 6, 411-423.	0.8	119
486	Alzheimer disease, the two-hit hypothesis: An update. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2007, 1772, 494-502.	1.8	251

#	Article	IF	Citations
487	Gonadotropins: A cohesive gender-based etiology of Alzheimer disease. Molecular and Cellular Endocrinology, 2007, 260-262, 271-275.	1.6	18
488	Increases in luteinizing hormone are associated with declines in cognitive performance. Molecular and Cellular Endocrinology, 2007, 269, 107-111.	1.6	103
489	Treating the Lesions, Not the Disease. American Journal of Pathology, 2007, 170, 1457-1459.	1.9	13
490	The Key Role of Oxidative Stress in Alzheimer's Disease. , 2007, , 267-281.		14
491	Three Histidine Residues of Amyloid-Î² Peptide Control the Redox Activity of Copper and Iron. Biochemistry, 2007, 46, 12737-12743.	1.2	175
492	Vascular oxidative stress in Alzheimer disease. Journal of the Neurological Sciences, 2007, 257, 240-246.	0.3	164
493	Lipoic Acid and N-acetyl Cysteine Decrease Mitochondrial-Related Oxidative Stress in Alzheimer Disease Patient Fibroblasts. Journal of Alzheimer's Disease, 2007, 12, 195-206.	1.2	176
494	Sir Martin Roth â€“ A Debt of Gratitude. Journal of Alzheimer's Disease, 2007, 11, 1-1.	1.2	0
495	Mitochondrial autophagocytosis in Alzheimer disease. Journal of Neuropathology and Experimental Neurology, 2007, 66, 434.	0.9	0
496	c-Jun phosphorylation in Alzheimer disease. Journal of Neuroscience Research, 2007, 85, 1668-1673.	1.3	75
497	Increased isoprostane and prostaglandin are prominent in neurons in Alzheimer disease. Molecular Neurodegeneration, 2007, 2, 2.	4.4	57
498	Conformational changes and cleavage of tau in Pick bodies parallel the early processing of tau found in Alzheimer pathology. Neuropathology and Applied Neurobiology, 2007, 34, 071027214335005-???.	1.8	44
499	Lipid peroxidation and 4-hydroxy-2-nonenal formation by copper ion bound to amyloid-Î² peptide. Free Radical Biology and Medicine, 2007, 43, 1552-1559.	1.3	81
500	Insights into amyloid-Î²-induced mitochondrial dysfunction in Alzheimer disease. Free Radical Biology and Medicine, 2007, 43, 1569-1573.	1.3	93
501	The role of novel chitin-like polysaccharides in Alzheimer disease. Neurotoxicity Research, 2007, 12, 269-274.	1.3	34
502	Causes of oxidative stress in Alzheimer disease. Cellular and Molecular Life Sciences, 2007, 64, 2202-2210.	2.4	312
503	Increased Expression of p130 in Alzheimer Disease. Neurochemical Research, 2007, 32, 639-644.	1.6	13
504	Indices of Metabolic Dysfunction and Oxidative Stress. Neurochemical Research, 2007, 32, 717-722.	1.6	23

#	Article	IF	Citations
505	Iron: The Redox-active Center of Oxidative Stress in Alzheimer Disease. Neurochemical Research, 2007, 32, 1640-1645.	1.6	169
506	The Pathology of Alzheimer Disease Elicits an In Vivo Immunological Response. American Journal of Immunology, 2007, 3, 10-14.	0.1	2
507	BRCA1 May Modulate Neuronal Cell Cycle Re-Entry in Alzheimer Disease. International Journal of Medical Sciences, 2007, 4, 140-145.	1.1	56
508	The Role of Oxidative Damage to Nucleic Acids in the Pathogenesis of Neurological Disease. , 2007, , 123-140.		2
509	The Potential Application of Antioxidant Agents in Alzheimer Disease Therapeutics. , 2007, , 194-211.		0
510	Mitochondrial Autophagocytosis in Alzheimer Disease. FASEB Journal, 2007, 21, A73.	0.2	0
511	Lipoic Acid and Nâ€Acetyl Cysteine Protect Against Mitochondrialâ€Related Oxidative Stress in Fibroblasts from Alzheimer Disease Patients. FASEB Journal, 2007, 21, .	0.2	0
512	Lipoic acid and N-acetyl cysteine protect against mitochondrial-related oxidative stress in fibroblasts from Alzheimer disease patients. Journal of Neuropathology and Experimental Neurology, 2007, 66, 434.	0.9	0
513	Protein Misfolding in Alzheimer's Disease. Enzyme Inhibitors Series, 2007, , .	0.1	0
514	The Fallacy of Amyloid and Cognition in Alzheimer???s Disease. Drugs and Aging, 2006, 23, 179.	1.3	1
515	Antioxidant protection and neurodegenerative disease: The role of amyloid-Î² and tau. American Journal of Alzheimer's Disease and Other Dementias, 2006, 21, 126-130.	0.9	61
516	The Estrogen Myth. Drugs in R and D, 2006, 7, 187-193.	1.1	25
517	Amyloid-Î² Vaccination: Testing the Amyloid Hypothesis?. American Journal of Pathology, 2006, 169, 738-739.	1.9	20
518	Telomeres and telomerase in Alzheimer's disease: Epiphenomena or a new focus for therapeutic strategy?. , 2006, 2, 164-168.		68
519	Commentary on â€œPerspective on a pathogenesis and treatment of Alzheimer's disease.â€•Therapeutic strategies for Alzheimer's disease: The need for a new era of innovation. , 2006, 2, ALZJJALZ200607002.		0
520	Emerging evidence for the neuroprotective role of Î±-synuclein. Experimental Neurology, 2006, 200, 1-7.	2.0	30
521	Î±-Synuclein facilitates the toxicity of oxidized catechol metabolites: Implications for selective neurodegeneration in Parkinson's disease. FEBS Letters, 2006, 580, 2147-2152.	1.3	47
522	Luteinizing hormone modulates cognition and amyloid-Î² deposition in Alzheimer APP transgenic mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2006, 1762, 447-452.	1.8	165

#	Article	IF	Citations
523	LC-MS display of the total modified amino acids in cataract lens proteins and in lens proteins glycated by ascorbic acid in vitro. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2006, 1762, 533-543.	1.8	38
524	Malignant glioma progression and nitric oxide. Neurochemistry International, 2006, 49, 764-768.	1.9	42
525	Nanoparticle iron chelators: A new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neuroscience Letters, 2006, 406, 189-193.	1.0	172
526	Clusterin up-regulation following sub-lethal oxidative stress and lipid peroxidation in human neuroblastoma cells. Neurobiology of Aging, 2006, 27, 1588-1594.	1.5	26
527	Compensatory responses induced by oxidative stress in Alzheimer disease. Biological Research, 2006, 39, 7-13.	1.5	39
528	Neurogenesis in Human Hippocampus: Implications for Alzheimer Disease Pathogenesis. Neuroembryology and Aging, 2006, 4, 175-182.	0.1	4
529	Solving the insoluble. Journal of Alzheimer's Disease, 2006, 9, 301-304.	1.2	4
530	Therapeutic potential of oxidative stress reduction in Alzheimer's disease. Future Neurology, 2006, 1, 1-4.	0.9	4
531	Involvement of Oxidative Stress in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2006, 65, 631-641.	0.9	484
532	Mitochondrial abnormalities and oxidative imbalance in Alzheimer disease. Journal of Alzheimer's Disease, 2006, 9, 147-153.	1.2	167
533	Steroidogenic acute regulatory protein (StAR): evidence of gonadotropin-induced steroidogenesis in Alzheimer disease. Molecular Neurodegeneration, 2006, 1, 14.	4.4	37
534	LRRK2 in Parkinson's disease and dementia with Lewy bodies. Molecular Neurodegeneration, 2006, 1, 17.	4.4	40
535	Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. Acta Neuropathologica, 2006, 111, 503-509.	3.9	127
536	Sequestration of p27 within the cytoplasm of cardiac myocytes in chronic ischemic heart disease: pathogenic implications for ischemic cardiomyopathy. Age, 2006, 28, 85-91.	3.0	1
537	Overexpression of GRK2 in alzheimer disease and in a chronic hypoperfusion rat model is an early marker of brain mitochondrial lesions. Neurotoxicity Research, 2006, 10, 43-56.	1.3	76
538	Presenilin mutation: A deadly first hit in Alzheimer disease. Free Radical Biology and Medicine, 2006, 40, 737-739.	1.3	6
539	Amyloid-Î², BACE, and oxidative stress in Alzheimer's disease, a commentary on â€œThe different aggregation state of beta-amyloid 1-42 mediates different effects on oxidative stress, neurodegeneration and BACE-1 expressionâ€• Free Radical Biology and Medicine, 2006, 41, 188-189.	1.3	6
540	Aberrant localization of importin Î±1 in hippocampal neurons in Alzheimer disease. Brain Research, 2006, 1124, 1-4.	1.1	51

#	Article	IF	Citations
541	The (un)balance between metabolic and oxidative abnormalities and cellular compensatory responses in Alzheimer disease. Mechanisms of Ageing and Development, 2006, 127, 501-506.	2.2	19
542	Ectopic expression of phospho-Smad2 in Alzheimer's disease: Uncoupling of the transforming growth factor-Î² pathway?. Journal of Neuroscience Research, 2006, 84, 1856-1861.	1.3	68
543	LRRK2 protein is a component of lewy bodies. Annals of Neurology, 2006, 60, 617-618.	2.8	57
544	Age-Related Loss of the DNA Repair Response Following Exposure to Oxidative Stress. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2006, 61, 427-434.	1.7	44
545	Therapeutic options in Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2006, 6, 897-910.	1.4	41
546	Heme Deficiency in Alzheimerâ€™s Disease: A Possible Connection to Porphyria. Journal of Biomedicine and Biotechnology, 2006, 2006, 1-5.	3.0	15
547	Apoptosis in Alzheimer Disease: A Mathematical Improbability. Current Alzheimer Research, 2006, 3, 393-396.	0.7	90
548	The Cell Cycle and Hormonal Fluxes in Alzheimer Disease: A Novel Therapeutic Target. Current Pharmaceutical Design, 2006, 12, 691-697.	0.9	20
549	Neurodegenerative Diseases: Mechanisms and Therapies. Journal of Biomedicine and Biotechnology, 2006, 2006, 1-2.	3.0	1
550	Foreword: Apoptotic Mechanisms in Neurodegenerative Diseases. Current Alzheimer Research, 2006, 3, 267-267.	0.7	0
551	Amyloid Beta: The Alternate Hypothesis. Current Alzheimer Research, 2006, 3, 75-80.	0.7	99
552	Targeting Gonadotropins: An Alternative Option for Alzheimer Disease Treatment. Journal of Biomedicine and Biotechnology, 2006, 2006, 1-8.	3.0	13
553	Oxidative Damage to RNA in Neurodegenerative Diseases. Journal of Biomedicine and Biotechnology, 2006, 2006, 1-6.	3.0	98
554	Neuropathology in Alzheimer's Disease: Awaking from a Hundred-Year-Old Dream. Science of Aging Knowledge Environment: SAGE KE, 2006, 2006, pe10-pe10.	0.9	11
555	Synaptic dysfunction and oxidative stress in Alzheimer's disease: Emerging mechanisms. Journal of Cellular and Molecular Medicine, 2006, 10, .	1.6	1
556	Cell Cycle Activation and the Amyloid-Î² Protein in Alzheimerâ€™s Disease. , 2006, , 299-308.		0
557	Neurogenesis in Alzheimerâ€™s Disease. , 2006, , 359-370.		0
558	Fractal analysis of monocytes in diabetes. Clinical Hemorheology and Microcirculation, 2006, 35, 269-72.	0.9	3

#	Article	IF	Citations
559	The Changing landscape of Alzheimerâ€™s disease: From Insoluble to Soluble and from Pathogen to Protector. , 2006, , 367-369.		0
560	Gender Differences in Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2005, 19, 95-99.	0.6	29
561	Insulin signaling, diabetes mellitus and risk of Alzheimer disease. Journal of Alzheimer's Disease, 2005, 7, 81-84.	1.2	45
562	Nuclear microscopy of diffuse plaques in the brains of transgenic mice. Nuclear Instruments & Methods in Physics Research B, 2005, 231, 326-332.	0.6	4
563	Oxidative Stress and Neurodegeneration. Annals of the New York Academy of Sciences, 2005, 1043, 545-552.	1.8	172
564	Raffinee in the Treatment of Spinal Cord Injury: An Open-Labeled Clinical Trial. Annals of the New York Academy of Sciences, 2005, 1042, 396-402.	1.8	7
565	Estrogen Bows to a New Master: The Role of Gonadotropins in Alzheimer Pathogenesis. Annals of the New York Academy of Sciences, 2005, 1052, 201-209.	1.8	43
566	Oxidative Imbalance in Alzheimer's Disease. Molecular Neurobiology, 2005, 31, 205-218.	1.9	126
567	beta-Site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. Journal of Neurochemistry, 2005, 92, 628-636.	2.1	311
568	Amyloid-Î² in Alzheimer's disease: the horse or the cart? Pathogenic or protective?. International Journal of Experimental Pathology, 2005, 86, 133-138.	0.6	54
569	Role of Amyloid-Î² in Alzheimer's Disease. International Journal of Experimental Pathology, 2005, 86, 131-131.	0.6	0
570	Alzheimer-specific epitopes of tau represent lipid peroxidation-induced conformations. Free Radical Biology and Medicine, 2005, 38, 746-754.	1.3	115
571	The cell cycle in Alzheimer disease: A unique target for neuropharmacology. Mechanisms of Ageing and Development, 2005, 126, 1019-1025.	2.2	97
572	Introduction: Imaging in Alzheimer's disease. Microscopy Research and Technique, 2005, 67, 113-113.	1.2	0
573	Mitogen- and stress-activated protein kinase 1: Convergence of the ERK and p38 pathways in Alzheimer's disease. Journal of Neuroscience Research, 2005, 79, 554-560.	1.3	30
574	MAPKs are differentially modulated in arctic ground squirrels during hibernation. Journal of Neuroscience Research, 2005, 80, 862-868.	1.3	35
575	Alzheimer?s disease: the impact of age-related changes in reproductive hormones. Cellular and Molecular Life Sciences, 2005, 62, 293-298.	2.4	42
576	Redox metals and oxidative abnormalities in human prion diseases. Acta Neuropathologica, 2005, 110, 232-238.	3.9	52

#	Article	IF	Citations
577	Oxidative stress mechanisms and potential therapeutics in Alzheimer disease. Journal of Neural Transmission, 2005, 112, 921-932.	1.4	113
578	Retinoic acid isomers protect hippocampal neurons from amyloid-Î² induced neurodegeneration. Neurotoxicity Research, 2005, 7, 243-250.	1.3	39
579	Neurotoxic dopamine quinone facilitates the assembly of tau into fibrillar polymers. Molecular and Cellular Biochemistry, 2005, 278, 203-212.	1.4	28
580	P38 Activation Mediates Amyloid-Î² Cytotoxicity. Neurochemical Research, 2005, 30, 791-796.	1.6	43
581	What is aging? What is its role in Alzheimer's disease? What can we do about it?. Journal of Alzheimer's Disease, 2005, 7, 247-253.	1.2	21
582	Alzheimers Disease and Oxidative Stress: The Old Problem Remains Unsolved. Current Medicinal Chemistry - Central Nervous System Agents, 2005, 5, 51-62.	0.6	16
583	Therapeutic Opportunities in Alzheimer Disease: One for all or all for One?. Current Medicinal Chemistry, 2005, 12, 1137-1147.	1.2	49
584	Ferric Cycle Activity and Alzheimer Disease. Current Neurovascular Research, 2005, 2, 261-267.	0.4	14
585	Chitin-like Polysaccharides in Alzheimers Disease Brains. Current Alzheimer Research, 2005, 2, 419-423.	0.7	46
586	Oxidative Stress: The Old Enemy in Alzheimers Disease Pathophysiology. Current Alzheimer Research, 2005, 2, 403-408.	0.7	117
587	Ribosomal RNA in Alzheimer Disease Is Oxidized by Bound Redox-active Iron. Journal of Biological Chemistry, 2005, 280, 20978-20986.	1.6	261
588	Redox Active Iron at the Center of Oxidative Stress in Alzheimer Disease. Letters in Drug Design and Discovery, 2005, 2, 479-482.	0.4	6
589	A Second Look into the Oxidant Mechanisms in Alzheimers Disease. Current Neurovascular Research, 2005, 2, 179-184.	0.4	11
590	The End of a Chilean Institute. Science, 2005, 308, 792b-793b.	6.0	0
591	Commentary: â€œCeramide and cholesterol: Possible connections between normal aging of the brain and Alzheimer's disease. Just hypotheses or molecular pathways to be identified?â€•By Claudio Costantini, Rekha M.K. Kolasani, and Luigi Puglielli. , 2005, 1, 51-52.		3
592	4-Oxo-2-nonenal Is Both More Neurotoxic and More Protein Reactive than 4-Hydroxy-2-nonenal. Chemical Research in Toxicology, 2005, 18, 1219-1231.	1.7	147
593	Tau phosphorylation in Alzheimer's disease: pathogen or protector?. Trends in Molecular Medicine, 2005, 11, 164-169.	3.5	224
594	Alzheimer's disease: an intracellular movement disorder?. Trends in Molecular Medicine, 2005, 11, 391-393.	3.5	18

#	Article	IF	Citations
595	Tau modifiers as therapeutic targets for Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1739, 211-215.	1.8	14
596	Effect of quinones on microtubule polymerization: a link between oxidative stress and cytoskeletal alterations in Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1740, 472-480.	1.8	38
597	Nanoparticle and other metal chelation therapeutics in Alzheimer disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1741, 246-252.	1.8	142
598	Concealment of epitope by reduction and alkylation in prion protein. Biochemical and Biophysical Research Communications, 2005, 326, 652-659.	1.0	14
599	Chronological primacy of oxidative stress in Alzheimer disease. Neurobiology of Aging, 2005, 26, 579-580.	1.5	49
600	Mitochondria DNA deletions in atherosclerotic hypoperfused brain microvessels as a primary target for the development of Alzheimer's disease. Journal of the Neurological Sciences, 2005, 229-230, 285-292.	0.3	55
601	Carnosine: A Versatile Antioxidant and Antiglycating Agent. Science of Aging Knowledge Environment: SAGE KE, 2005, 2005, pe12-pe12.	0.9	90
602	Oxidative damage and Alzheimer's disease: Are antioxidant therapies useful?. Drug News and Perspectives, 2005, 18, 5.	1.9	43
603	Ciprofloxacin Does Not Exert Nephrotoxicity in Rats. American Journal of Infectious Diseases, 2005, 1, 145-148.	0.1	0
604	Amyloid- _ and _ in Alzheimerâ€™s Disease. Oxidative Stress and Disease, 2005, , 121-129.	0.3	0
605	Temporal Primacy of Oxidative Stress in the Pathological Cascade of Alzheimer Disease. Oxidative Stress and Disease, 2005, , 365-372.	0.3	0
606	Oxidative Adaptation in Aging and Alzheimerâ€™s Disease. Oxidative Stress and Disease, 2005, , 117-125.	0.3	0
607	Metal ions and oxidative protein modification in neurological disease. Annali Dell'Istituto Superiore Di Sanita, 2005, 41, 143-64.	0.2	86
608	Therapeutic potential of oxidant mechanisms in Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2004, 4, 995-1004.	1.4	16
609	Drug Therapy in Alzheimer's Disease. New England Journal of Medicine, 2004, 351, 1911-1913.	13.9	15
610	Oxidative Stress Mechanisms and Potential Therapeutic Modalities in Alzheimer Disease. Medicinal Chemistry Reviews Online, 2004, 1, 19-23.	0.1	2
611	Assembly In Vitro of Tau Protein and its Implications in Alzheimers Disease. Current Alzheimer Research, 2004, 1, 97-101.	0.7	27
612	Heme Catabolism and Heme Oxygenase in Neurodegenerative Disease. Antioxidants and Redox Signaling, 2004, 6, 888-894.	2.5	34

#	Article	IF	Citations
613	Is nitric oxide a key target in the pathogenesis of brain lesions during the development of Alzheimer's disease?. Neurological Research, 2004, 26, 547-553.	0.6	28
614	Luteinizing Hormone, a Reproductive Regulator That Modulates the Processing of Amyloid-Î² Precursor Protein and Amyloid-Î² Deposition. Journal of Biological Chemistry, 2004, 279, 20539-20545.	1.6	154
615	Regulation of glycogen synthase kinase-3beta by products of lipid peroxidation in human neuroblastoma cells. Journal of Neurochemistry, 2004, 89, 1224-1232.	2.1	40
616	Neuroprotective properties of Bcl-w in Alzheimer disease. Journal of Neurochemistry, 2004, 89, 1233-1240.	2.1	54
617	Oxidative damage in cultured human olfactory neurons from Alzheimer's disease patients. Aging Cell, 2004, 3, 41-44.	3.0	87
618	Metal Ions and Neurodegenerative Diseases Paolo Zatta, Editor. World Scientific Publishing Co. Pte. Ltd, Singapore, 2004, pp 400. Aging Cell, 2004, 3, 85-85.	3.0	0
619	Alzheimer's disease: the two-hit hypothesis. Lancet Neurology, The, 2004, 3, 219-226.	4.9	402
620	Homocysteine and Alzheimer's disease: a modifiable risk?. Free Radical Biology and Medicine, 2004, 36, 1471-1475.	1.3	52
621	Accelerated Î±-synuclein aggregation after differentiation of SH-SY5Y neuroblastoma cells. Brain Research, 2004, 1013, 51-59.	1.1	78
622	Challenging the Amyloid Cascade Hypothesis: Senile Plaques and Amyloid-Î² as Protective Adaptations to Alzheimer Disease. Annals of the New York Academy of Sciences, 2004, 1019, 1-4.	1.8	169
623	Oxidative Stress and Redox-Active Iron in Alzheimer's Disease. Annals of the New York Academy of Sciences, 2004, 1012, 179-182.	1.8	179
624	Aberrant expression of metabotropic glutamate receptor 2 in the vulnerable neurons of Alzheimerâ€™s disease. Acta Neuropathologica, 2004, 107, 365-371.	3.9	60
625	Neurofilament proteins in neurodegenerative diseases. Cellular and Molecular Life Sciences, 2004, 61, 3057-3075.	2.4	135
626	Prion protein is ubiquitinated after developing protease resistance in the brains of scrapie-infected mice. Journal of Pathology, 2004, 203, 603-608.	2.1	48
627	Distribution, levels, and activation of MEK1 in Alzheimer's disease. Journal of Neurochemistry, 2004, 86, 136-142.	2.1	55
628	Elevated expression of a regulator of the G2/M phase of the cell cycle, neuronal CIP-1-associated regulator of cyclin B, in Alzheimer's disease. Journal of Neuroscience Research, 2004, 75, 698-703.	1.3	63
629	Copper Mediates Dityrosine Cross-Linking of Alzheimer's Amyloid-Î². Biochemistry, 2004, 43, 560-568.	1.2	362
630	P4-250 Redox-active iron oxidizes ribosomal RNa in neurons vulnerable to Alzheimer's disease. Neurobiology of Aging, 2004, 25, S546.	1.5	0

#	Article	IF	Citations
631	P3-275 Phosphorylation dependent control of oxidative modification in Alzheimer disease. Neurobiology of Aging, 2004, 25, S432-S433.	1.5	0
632	P4-242 Oxidative damage in ferritin-induced neurodegeneration. Neurobiology of Aging, 2004, 25, S544.	1.5	0
633	In Situ Localization of Nonenzymatic Peroxidaseâ€Like Activity of Tissueâ€Bound Transition Metals. Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al], 2004, 20, Unit17.4.	1.1	2
634	Mitochondrial failures in Alzheimer's disease. American Journal of Alzheimer's Disease and Other Dementias, 2004, 19, 345-352.	0.9	111
635	Cerebral amyloid angiopathy: major contributor or decorative response to Alzheimerâ€™s disease pathogenesis. Neurobiology of Aging, 2004, 25, 599-602.	1.5	54
636	Staying Connected. American Journal of Pathology, 2004, 165, 1461-1464.	1.9	18
637	Mitochondria as a primary target for vascular hypoperfusion and oxidative stress in Alzheimer's disease. Mitochondrion, 2004, 4, 649-663.	1.6	77
638	Neuronal RNA oxidation is a prominent feature of familial Alzheimer's disease. Neurobiology of Disease, 2004, 17, 108-113.	2.1	141
639	Contribution of redox-active iron and copper to oxidative damage in Alzheimer disease. Ageing Research Reviews, 2004, 3, 319-326.	5.0	94
640	Oxidative stress signalling in Alzheimer's disease. Brain Research, 2004, 1000, 32-39.	1.1	377
641	P1-266 The critical role of the ERK pathway in the pathogenesis of Alzheimer's disease. Neurobiology of Aging, 2004, 25, S172.	1.5	1
642	Alzheimer disease: Evidence for a central pathogenic role of iron-mediated reactive oxygen species. Journal of Alzheimer's Disease, 2004, 6, 165-169.	1.2	100
643	Oxidative Stress in Alzheimer Disease: The Earliest Cytological and Biochemical Feature. , 2004, , 164-171.		0
644	Perspectives on the Amyloid-Î² Cascade Hypothesis. Journal of Alzheimer's Disease, 2004, 6, 137-145.	1.2	56
645	Beyond Estrogen: Targeting Gonadotropin Hormones in the Treatment of Alzheimers Disease. CNS and Neurological Disorders, 2004, 3, 281-285.	4.3	33
646	Nutritional Antioxidants, Vitamins, Cognition, and Neurodegenerative Disease. , 2004, , 813-823.		0
647	Mechanisms Involved in Gender Differences in Alzheimer's Disease: The Role of Leuteinizing and Follicle Stimulating Hormones. , 2004, , 1234-1237.		3
648	Tau phosphorylation and assembly. Acta Neurobiologiae Experimentalis, 2004, 64, 33-9.	0.4	13

#	Article	IF	Citations
649	Sources and mechanisms of cytoplasmic oxidative damage in Alzheimer's disease. Acta Neurobiologiae Experimentalis, 2004, 64, 81-7.	0.4	20
650	The role of metabotropic glutamate receptors in Alzheimer's disease. Acta Neurobiologiae Experimentalis, 2004, 64, 89-98.	0.4	36
651	Gonadotropins and Alzheimer's disease: the link between estrogen replacement therapy and neuroprotection. Acta Neurobiologiae Experimentalis, 2004, 64, 113-8.	0.4	10
652	The role of nitric oxide in the pathogenesis of brain lesions during the development of Alzheimer's disease. In Vivo, 2004, 18, 325-33.	0.6	21
653	Tipping the Apoptotic Balance in Alzheimer's Disease: The Abortosis Concept. Cell Biochemistry and Biophysics, 2003, 39, 249-256.	0.9	19
654	A metabolic basis for Alzheimer disease. Neurochemical Research, 2003, 28, 1549-1552.	1.6	51
655	Adventiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer disease. BioMetals, 2003, 16, 77-81.	1.8	94
656	Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Alzheimer disease. Neurotoxicity Research, 2003, 5, 491-504.	1.3	134
657	Ectopic localization of phosphorylated histone H3 in Alzheimer's disease: a mitotic catastrophe?. Acta Neuropathologica, 2003, 105, 524-528.	3.9	155
658	Oxidative stress and predominant AÎ²42(43) deposition in myopathies with rimmed vacuoles. Acta Neuropathologica, 2003, 105, 581-585.	3.9	31
659	Oxidative damage in the olfactory system in Alzheimer's disease. Acta Neuropathologica, 2003, 106, 552-556.	3.9	67
660	Reduction of inclusion body pathology in ApoE-deficient mice fed a combination of antioxidants. Free Radical Biology and Medicine, 2003, 34, 1070-1077.	1.3	46
661	Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells. Journal of Neuroscience Research, 2003, 71, 863-870.	1.3	121
662	JKK1, an upstream activator of JNK/SAPK, is activated in Alzheimer's disease. Journal of Neurochemistry, 2003, 85, 87-93.	2.1	60
663	Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. Journal of Neurochemistry, 2003, 85, 1101-1108.	2.1	295
664	4â€Hydroxynonenal contributes to NGF withdrawalâ€induced neuronal apoptosis. Journal of Neurochemistry, 2003, 85, 999-1005.	2.1	17
665	Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. Journal of Neurochemistry, 2003, 86, 1312-1312.	2.1	3
666	Amyloid-Î²-induced toxicity of primary neurons is dependent upon differentiation-associated increases in tau and cyclin-dependent kinase 5 expression. Journal of Neurochemistry, 2003, 88, 554-563.	2.1	77

#	Article	IF	Citations
667	Increased p27, an essential component of cell cycle control, in Alzheimer's disease. Aging Cell, 2003, 2, 105-110.	3.0	88
668	Metal Binding and Oxidation of Amyloid-Î² within Isolated Senile Plaque Cores:Â Raman Microscopic Evidenceâ€. Biochemistry, 2003, 42, 2768-2773.	1.2	543
669	Microtubule Reduction in Alzheimer's Disease and Aging Is Independent of Ï„ Filament Formation. American Journal of Pathology, 2003, 162, 1623-1627.	1.9	294
670	Hydroxynonenal, toxic carbonyls, and Alzheimer disease. Molecular Aspects of Medicine, 2003, 24, 305-313.	2.7	94
671	Role of high mobility group protein-1 (HMG1) in amyloid-Î² homeostasis. Biochemical and Biophysical Research Communications, 2003, 301, 699-703.	1.0	85
672	Apoptotic promoters and inhibitors in Alzheimer's disease: Who wins out?. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 251-254.	2.5	41
673	Possible involvement of Wiskottâ€“Aldrich syndrome protein family in aberrant neuronal sprouting in Alzheimer's disease. Neuroscience Letters, 2003, 346, 149-152.	1.0	21
674	Amyloid-Î²: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-Î². Brain Research Reviews, 2003, 43, 1-16.	9.1	271
675	Cerebrovascular requirement for sealant, anti-coagulant and remodeling molecules that allow for the maintenance of vascular integrity and blood supply. Brain Research Reviews, 2003, 43, 164-178.	9.1	54
676	Estrogen Replacement and Risk of Alzheimer DiseaseEstrogen Replacement and Risk of Alzheimer Disease. JAMA - Journal of the American Medical Association, 2003, 289, 1100.	3.8	16
677	Oxidative Stress and Neuronal Adaptation in Alzheimer Disease: The Role of SAPK Pathways. Antioxidants and Redox Signaling, 2003, 5, 571-576.	2.5	67
678	Amyotrophic lateral sclerosis: a novel hypothesis involving a gained 'loss of function' in the JNK/SAPK pathway. Redox Report, 2003, 8, 129-133.	1.4	4
679	Mitochondria and vascular lesions as a central target for the development of Alzheimer's disease and Alzheimer disease-like pathology in transgenic mice. Neurological Research, 2003, 25, 665-674.	0.6	93
680	Cerebral Hemorrhage and Amyloid-<FONT FACE=. Science, 2003, 299, 1014a-1014.	6.0	23
681	CORRECTIONS AND CLARIFICATIONS. Science, 2003, 299, 1014b-1015.	6.0	5
682	Amyloids, Aggregates and Neuronal Inclusions: Good or Bad News for Neurons?. Current Medicinal Chemistry Immunology, Endocrine & Metabolic Agents, 2003, 3, 293-298.	0.2	4
683	Functional Implications of Antiestrogen Induction of Quinone Reductase: Inhibition of Estrogen-Induced Deoxyribonucleic Acid Damage. Molecular Endocrinology, 2003, 17, 1344-1355.	3.7	43
684	Hypoperfusion, Mitochondria Failure, Oxidative Stress, and Alzheimer Disease. Journal of Biomedicine and Biotechnology, 2003, 2003, 162-163.	3.0	28

#	Article	IF	Citations
685	Will Preventing Protein Aggregates Live Up to Its Promise as Prophylaxis Against Neurodegenerative Diseases?. Brain Pathology, 2003, 13, 630-638.	2.1	24
686	Metal-Catalyzed Redox Activity in Neurodegenerative Disease. , 2003, , 1-14.		1
687	Metal Homeostasis and Its Relation to Oxidative Stress in Alzheimerâ€™s Disease. Oxidative Stress and Disease, 2003, , .	0.3	0
688	Differential Regulation of Glutamate Receptors in Alzheimerâ€™s Disease. NeuroSignals, 2002, 11, 282-292.	0.5	34
689	High Molecular Weight Neurofilament Proteins Are Physiological Substrates of Adduction by the Lipid Peroxidation Product Hydroxynonenal. Journal of Biological Chemistry, 2002, 277, 4644-4648.	1.6	122
690	Iron: A Pathological Mediator of Alzheimer Disease?. Developmental Neuroscience, 2002, 24, 184-187.	1.0	127
691	Microglial activation and amyloidâ€Î² clearance induced by exogenous heatâ€shock proteins. FASEB Journal, 2002, 16, 601-603.	0.2	299
692	Neuronal RNA oxidation is a prominent feature of dementia with Lewy bodies. NeuroReport, 2002, 13, 2035-2039.	0.6	70
693	Signal Transduction in Alzheimerâ€™s Disease. NeuroSignals, 2002, 11, 235-235.	0.5	2
694	Apoptotic and Oxidative Indicators in Alzheimer's Disease. , 2002, , 225-246.		4
695	Systemic Increase of Oxidative Nucleic Acid Damage in Parkinson's Disease and Multiple System Atrophy. Neurobiology of Disease, 2002, 9, 244-248.	2.1	258
696	Oxidative Damage to Nucleic Acids in Human Prion Disease. Neurobiology of Disease, 2002, 9, 275-281.	2.1	68
697	Oxidative Stress Increases Expression and Activity of BACE in NT2 Neurons. Neurobiology of Disease, 2002, 10, 279-288.	2.1	355
698	The Role of Mitogen-Activated Protein Kinase Pathways in Alzheimerâ€™s Disease. NeuroSignals, 2002, 11, 270-281.	0.5	336
699	The Role of Iron and Copper in the Aetiology of Neurodegenerative Disorders. CNS Drugs, 2002, 16, 339-352.	2.7	115
700	Predicting the failure of amyloid-Î² vaccine. Lancet, The, 2002, 359, 1864-1865.	6.3	52
701	Role of the antioxidant ascorbate in hibernation and warming from hibernation. Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology, 2002, 133, 483-492.	1.3	53
702	Comparative biology and pathology of oxidative stress in Alzheimer and other neurodegenerative diseases: beyond damage and response. Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology, 2002, 133, 507-513.	1.3	59

#	Article	IF	Citations
703	The â€œDown'sâ€•Side of Mitochondria. Developmental Cell, 2002, 2, 255-256.	3.1	15
704	The state versus amyloid-Î²: the trial of the most wanted criminal in Alzheimer disease. Peptides, 2002, 23, 1333-1341.	1.2	88
705	Senile plaque composition and posttranslational modification of amyloid-Î² peptide and associated proteins. Peptides, 2002, 23, 1343-1350.	1.2	133
706	Amyloid-Î², tau alterations and mitochondrial dysfunction in Alzheimer disease: the chickens or the eggs?. Neurochemistry International, 2002, 40, 527-531.	1.9	70
707	The p38 pathway is activated in Pick disease and progressive supranuclear palsy: a mechanistic link between mitogenic pathways, oxidative stress, and tau. Neurobiology of Aging, 2002, 23, 855-859.	1.5	43
708	Amyloid-Î²: a (life) preserver for the brain. Neurobiology of Aging, 2002, 23, 1097-1099.	1.5	45
709	Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans. Neuroscience Letters, 2002, 319, 25-28.	1.0	164
710	Alzheimer Disease and Oxidative Stress. Journal of Biomedicine and Biotechnology, 2002, 2, 120-123.	3.0	380
711	Causes and consequences of oxidative stress in Alzheimerâ€™s disease 1,2 1Guest Editors: Mark A. Smith and George Perry 2This article is part of a series of reviews on â€œCauses and Consequences of Oxidative Stress in Alzheimerâ€™s Disease.â€•The full list of papers may be found on the homepage of the journal.. Free Radical Biology and Medicine, 2002, 32, 1049.	1.3	49
712	Cholesterol, oxidative stress, and Alzheimerâ€™s disease: expanding the horizons of pathogenesis1 1This article is part of a series of reviews on â€œCauses and Consequences of Oxidative Stress in Alzheimerâ€™s Disease.â€•The full list of papers may be found on the homepage of the journal.. Free Radical Biology and Medicine, 2002, 33, 173-181.	1.3	70
713	Amyloid-Î² and Ï„ serve antioxidant functions in the aging and Alzheimer brain. Free Radical Biology and Medicine, 2002, 33, 1194-1199.	1.3	194
714	Is oxidative damage the fundamental pathogenic mechanism of Alzheimerâ€™s and other neurodegenerative diseases?. Free Radical Biology and Medicine, 2002, 33, 1475-1479.	1.3	266
715	Ill-fated amyloid-? vaccine. Journal of Neuroscience Research, 2002, 69, 285-285.	1.3	9
716	Amyloid-?: A vascular sealant that protects against hemorrhage?. Journal of Neuroscience Research, 2002, 70, 356-356.	1.3	40
717	Role of mitochondrial dysfunction in Alzheimer's disease. Journal of Neuroscience Research, 2002, 70, 357-360.	1.3	324
718	Elevated luteinizing hormone expression colocalizes with neurons vulnerable to Alzheimer's disease pathology. Journal of Neuroscience Research, 2002, 70, 514-518.	1.3	122
719	Metals and oxidative homeostasis in Alzheimer's disease. Drug Development Research, 2002, 56, 293-299.	1.4	22
720	Dangers of the amyloid-Î² vaccination. Acta Neuropathologica, 2002, 104, 110-110.	3.9	4

#	Article	IF	Citations
721	The neuroprotective activities of melatonin against the Alzheimer Î²-protein are not mediated by melatonin membrane receptors. Journal of Pineal Research, 2002, 32, 135-142.	3.4	83
722	In Alzheimer's Disease, Heme Oxygenase Is Coincident with Alz50, an Epitope of Ï„ Induced by 4-Hydroxy-2-Nonenal Modification. Journal of Neurochemistry, 2002, 75, 1234-1241.	2.1	189
723	Formation of aberrant phosphotau fibrillar polymers in neural cultured cells. FEBS Journal, 2002, 269, 1484-1489.	0.2	92
724	Call for Elan to publish Alzheimer's trial details. Nature, 2002, 416, 677-677.	13.7	22
725	Atherosclerotic Lesions and Mitochondria DNA Deletions in Brain Microvessels as a Central Target for the Development of Human AD and ADâ€Like Pathology in Aged Transgenic Mice. Annals of the New York Academy of Sciences, 2002, 977, 45-64.	1.8	88
726	Involvement of maillard reactions in Alzheimer disease. Neurotoxicity Research, 2002, 4, 191-209.	1.3	100
727	The Role of Oxidative Stress in the Pathophysiology of Cerebrovascular Lesions in Alzheimer's Disease. Brain Pathology, 2002, 12, 21-35.	2.1	146
728	Prion and Alzheimer Diseases: The Road to Pathogenesis is Paved with Copper. , 2002, , 96-101.		1
729	Mitochondrial Abnormalities and Oxidative Imbalance in Neurodegenerative Disease. Science of Aging Knowledge Environment: SAGE KE, 2002, 2002, 16pe-16.	0.9	23
730	Melatonin exhibits antioxidant properties in a mouse brain slice model of excitotoxicity. International Journal of Circumpolar Health, 2002, 61, 32-40.	0.5	9
731	Role of Heme Catabolism in Neurodegenerative Diseases. , 2002, , 135-143.		0
732	Neuronal Survival and Death in Alzheimer Disease. Advances in Behavioral Biology, 2002, , 49-57.	0.2	0
733	Labeling of cerebral amyloid beta deposits in vivo using intranasal basic fibroblast growth factor and serum amyloid P component in mice. Journal of Nuclear Medicine, 2002, 43, 1044-51.	2.8	30
734	Induction of HO-1 and NOS in Doppel-Expressing Mice Devoid of PrP: Implications for Doppel Function. Molecular and Cellular Neurosciences, 2001, 17, 768-775.	1.0	62
735	Do Neurons Have a Choice in Death?. American Journal of Pathology, 2001, 158, 1-2.	1.9	37
736	Hibernation, a Model of Neuroprotection. American Journal of Pathology, 2001, 158, 2145-2151.	1.9	131
737	A diet at amyloid beta?. Neurobiology of Aging, 2001, 22, 161-163.	1.5	8
738	Copernicus revisited: amyloid beta in Alzheimer's disease. Neurobiology of Aging, 2001, 22, 131-146.	1.5	190

#	Article	IF	Citations
739	Mechanisms by which metals promote events connected to neurodegenerative diseases. Brain Research Bulletin, 2001, 55, 125-132.	1.4	97
740	Diabetes-Associated Sustained Activation of the Transcription Factor Nuclear Factor-ÂB. Diabetes, 2001, 50, 2792-2808.	0.3	782
741	Journal of Alzheimer's Disease Established as a Leading Journal. Journal of Alzheimer's Disease, 2001, 3, 521-523.	1.2	0
742	Hibernation, a Model of Neuroprotection. Scientific World Journal, The, 2001, 1, 108-108.	0.8	3
743	Melatonin acts as antioxidant and pro-oxidant in an organotypic slice culture model of Alzheimer's disease. NeuroReport, 2001, 12, 1277-1280.	0.6	42
744	Increased levels of oxidative stress markers detected in the brains of mice devoid of prion protein. Journal of Neurochemistry, 2001, 76, 565-572.	2.1	163
745	Activation and redistribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. Journal of Neurochemistry, 2001, 76, 435-441.	2.1	419
746	Induction of NADPH cytochrome P450 reductase by the Alzheimer Î²-protein. Amyloid as a â€˜foreign bodyâ€™. Journal of Neurochemistry, 2001, 78, 121-128.	2.1	17
747	In Situ Oxidative Catalysis by Neurofibrillary Tangles and Senile Plaques in Alzheimerâ€™s Disease. Journal of Neurochemistry, 2001, 74, 270-279.	2.1	485
748	Atherosclerotic Lesions Are Associated with Increased Immunoreactivity for Inducible Nitric Oxide Synthase and Endothelin-1 in Thoracic Aortic Intimal Cells of Hyperlipidemic Watanabe Rabbits. Experimental and Molecular Pathology, 2001, 71, 40-54.	0.9	33
749	Abortive apoptosis in Alzheimer's disease. Acta Neuropathologica, 2001, 101, 305-310.	3.9	146
750	Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the â€˜two hitâ€™ hypothesis. Mechanisms of Ageing and Development, 2001, 123, 39-46.	2.2	293
751	Melatonin reduces interleukin secretion in amyloid-Î² stressed mouse brain slices. Chemico-Biological Interactions, 2001, 134, 101-107.	1.7	31
752	Redox-active iron mediates amyloid-Î² toxicity. Free Radical Biology and Medicine, 2001, 30, 447-450.	1.3	356
753	Erythrocyte, plasma, and serum antioxidant activities in untreated toxic multinodular goiter patients. Free Radical Biology and Medicine, 2001, 30, 665-670.	1.3	29
754	Active glycation in neurofibrillary pathology of Alzheimer disease: NÎµ-(Carboxymethyl) lysine and hexitol-lysine. Free Radical Biology and Medicine, 2001, 31, 175-180.	1.3	194
755	Oxidative Damage Is the Earliest Event in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2001, 60, 759-767.	0.9	1,670
756	Effect of the herbicide 4-CPA on human erythrocyte antioxidant enzymesin vitro. Redox Report, 2001, 6, 153-154.	1.4	3

#	Article	IF	Citations
757	Chemistry and Biochemistry of Oxidative Stress in Neurodegenerative Disease. Current Medicinal Chemistry, 2001, 8, 721-738.	1.2	573
758	Biochemistry of Neurodegeneration. Science, 2001, 291, 595c-597.	6.0	13
759	Mitochondrial Abnormalities in Alzheimer's Disease. Journal of Neuroscience, 2001, 21, 3017-3023.	1.7	1,179
760	Activation of p38 Kinase Links Tau Phosphorylation, Oxidative Stress, and Cell Cycle-Related Events in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2000, 59, 880-888.	0.9	328
761	Oxidative Stress, Antioxidants, and Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2000, 14, S62-S66.	0.6	79
762	Decreased constitutive nitric oxide synthase, but increased inducible nitric oxide synthase and endothelin-1 immunoreactivity in aortic endothelial cells of Donryu rats on a cholesterol-enriched diet. The Anatomical Record, 2000, 260, 16-25.	2.3	22
763	How important is oxidative damage? Lessons from Alzheimerâ€™s disease. Free Radical Biology and Medicine, 2000, 28, 831-834.	1.3	247
764	Will antioxidants fulfill their expectations for the treatment of Alzheimer disease?. Mechanisms of Ageing and Development, 2000, 116, 169-179.	2.2	29
765	Sequestration of iron by Lewy bodies in Parkinson's disease. Acta Neuropathologica, 2000, 100, 111-114.	3.9	223
766	Evidence for a Novel Heme-Binding Protein, HasAh, in Alzheimer Disease. Antioxidants and Redox Signaling, 2000, 2, 137-142.	2.5	19
767	Overexpression of Heme Oxygenase in Neuronal Cells, the Possible Interaction with Tau. Journal of Biological Chemistry, 2000, 275, 5395-5399.	1.6	171
768	Metabolic, Metallic, and Mitotic Sources of Oxidative Stress in Alzheimer Disease. Antioxidants and Redox Signaling, 2000, 2, 413-420.	2.5	145
769	Histochemical and Immunocytochemical Approaches to the Study of Oxidative Stress. Clinical Chemistry and Laboratory Medicine, 2000, 38, 93-7.	1.4	12
770	Evidence that the Î²-Amyloid Plaques of Alzheimer's Disease Represent the Redox-silencing and Entombment of AÎ² by Zinc. Journal of Biological Chemistry, 2000, 275, 19439-19442.	1.6	366
771	Neuronal Oxidative Stress Precedes Amyloid-Î² Deposition in Down Syndrome. Journal of Neuropathology and Experimental Neurology, 2000, 59, 1011-1017.	0.9	307
772	Lipoperoxidation Is Selectively Involved in Progressive Supranuclear Palsy. Journal of Neuropathology and Experimental Neurology, 2000, 59, 393-397.	0.9	82
773	Protein Disulfide Isomerase in Alzheimer Disease. Antioxidants and Redox Signaling, 2000, 2, 485-489.	2.5	53
774	Identification of Ubiquilin, a Novel Presenilin Interactor That Increases Presenilin Protein Accumulation. Journal of Cell Biology, 2000, 151, 847-862.	2.3	205

#	Article	IF	Citations
775	Activation of NADPH Oxidase in Alzheimer's Disease Brains. Biochemical and Biophysical Research Communications, 2000, 273, 5-9.	1.0	275
776	Amyloid-Î² junkies. Lancet, The, 2000, 355, 757.	6.3	79
777	Vascular abnormalities: the insidious pathogenesis of Alzheimerâ€™s diseaseâ˜†. Neurobiology of Aging, 2000, 21, 357-361.	1.5	91
778	Oxidative stress in Alzheimerâ€™s disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2000, 1502, 139-144.	1.8	668
779	Oxidative damage in Alzheimer's disease: the metabolic dimension. International Journal of Developmental Neuroscience, 2000, 18, 417-421.	0.7	106
780	Arson: Tracking the Culprit in Alzheimer's Disease. Annals of the New York Academy of Sciences, 2000, 924, 35-38.	1.8	60
781	RNA Oxidation Is a Prominent Feature of Vulnerable Neurons in Alzheimerâ€™s Disease. Journal of Neuroscience, 1999, 19, 1959-1964.	1.7	708
782	Diet and Oxidative Stress: A Novel Synthesis of Epidemiological Data on Alzheimer's Disease*. Journal of Alzheimer's Disease, 1999, 1, 203-206.	1.2	59
783	Quinone reductase (NQO1), a sensitive redox indicator, is increased in Alzheimer's disease. Redox Report, 1999, 4, 23-27.	1.4	111
784	RNA Oxidation in Alzheimer and Parkinson Diseases. Rejuvenation Research, 1999, 2, 227-230.	0.2	10
785	Prion Protein Glycosylation Is Sensitive to Redox Change. Journal of Biological Chemistry, 1999, 274, 34846-34850.	1.6	63
786	Redox metals and neu rodegenerative disease. Current Opinion in Chemical Biology, 1999, 3, 220-225.	2.8	211
787	Neuronal RNA Oxidation in Alzheimer's Disease and Down's Syndrome. Annals of the New York Academy of Sciences, 1999, 893, 362-364.	1.8	107
788	Is increased redox-active iron in Alzheimer disease a failure of the copper-binding protein ceruloplasmin?. Free Radical Biology and Medicine, 1999, 26, 1508-1512.	1.3	72
789	Mitochondrial abnormalities: A primary basis for oxidative damage in Alzheimer's disease. Drug Development Research, 1999, 46, 26-33.	1.4	15
790	The mosaic of brain glial hyperactivity during normal ageing and its attenuation by food restriction. Neuroscience, 1999, 89, 687-699.	1.1	177
791	[10] In situ methods for detection and localization of markers of oxidative stress: Application in neurodegenerative disorders. Methods in Enzymology, 1999, 309, 133-152.	0.4	45
792	Universal Isolation of Cross-Linked Peptides:â€‰ Application to Neurofibrillary Tangles. Bioconjugate Chemistry, 1999, 10, 112-118.	1.8	6

#	Article	IF	Citations
793	Parkinson's Disease Is Associated with Oxidative Damage to Cytoplasmic DNA and RNA in Substantia Nigra Neurons. American Journal of Pathology, 1999, 154, 1423-1429.	1.9	570
794	Increased Neuronal Glucose-6-phosphate Dehydrogenase and Sulfhydryl Levels Indicate Reductive Compensation to Oxidative Stress in Alzheimer Disease. Archives of Biochemistry and Biophysics, 1999, 370, 236-239.	1.4	116
795	Role of Oxidative Stress in Frontotemporal Dementia. Dementia and Geriatric Cognitive Disorders, 1999, 10, 85-87.	0.7	30
796	Genetic evidence for oxidative stress in AlzheimerÊ¼s disease. NeuroReport, 1999, 10, 1355-1357.	0.6	18
797	Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation. NeuroReport, 1999, 10, 2411-2415.	0.6	278
798	Serum amyloid P is not present in amyloid Î² deposits of a transgenic animal modela. NeuroReport, 1999, 10, 3229-3232.	0.6	19
799	Asking the Right Questions. Science, 1999, 285, 663-663.	6.0	0
800	Cytochemical Demonstration of Oxidative Damage in Alzheimer Disease by Immunochemical Enhancement of the Carbonyl Reaction with 2,4-Dinitrophenylhydrazine. Journal of Histochemistry and Cytochemistry, 1998, 46, 731-735.	1.3	234
801	A suicide note from Alzheimer disease neurons?. Nature Medicine, 1998, 4, 897-898.	15.2	107
802	Alteration of proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-1 and CPP32, in Alzheimer's disease. Brain Research, 1998, 780, 260-269.	1.1	244
803	Abnormal localization of iron regulatory protein in Alzheimer's disease. Brain Research, 1998, 788, 232-236.	1.1	173
804	Cerebrovascular muscle atrophy is a feature of Alzheimer's disease. Brain Research, 1998, 791, 63-66.	1.1	70
805	Striation is the characteristic neuritic abnormality in Alzheimer disease. Brain Research, 1998, 813, 329-333.	1.1	32
806	Dimethylargininase, a nitric oxide regulatory protein, in Alzheimer disease. Free Radical Biology and Medicine, 1998, 25, 898-902.	1.3	48
807	Alzheimer's disease â€“ synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. Journal of Neural Transmission, 1998, 105, 439.	1.4	256
808	Clâ¯-ATPase and Na+/K+-ATPase activities in Alzheimer's disease brains. Neuroscience Letters, 1998, 254, 141-144.	1.0	120
809	What are the facts and artifacts of the pathogenensis and etiology of Alzheimer disease?. Journal of Chemical Neuroanatomy, 1998, 16, 35-41.	1.0	36
810	Early Glycoxidation Damage in Brains from Down's Syndrome. Biochemical and Biophysical Research Communications, 1998, 243, 849-851.	1.0	120

#	Article	IF	Citations
811	Astrocytes Regulate Microglial Phagocytosis of Senile Plaque Cores of Alzheimer's Disease. Experimental Neurology, 1998, 149, 329-340.	2.0	221
812	Altered Glycosylation Pattern of Proteins in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 1998, 57, 905-914.	0.9	54
813	Reactive Oxygen Species Mediate Cellular Damage in Alzheimer Disease. Journal of Alzheimer's Disease, 1998, 1, 45-55.	1.2	185
814	Amyloidâ€Î² Deposition in Alzheimer Transgenic Mice Is Associated with Oxidative Stress. Journal of Neurochemistry, 1998, 70, 2212-2215.	2.1	499
815	Neuronal Oxidative Stress is a Common Feature of Alzheimerâ€™s and Parkinsonâ€™s Diseases. Advances in Behavioral Biology, 1998, , 77-80.	0.2	1
816	The Role of Oxidative Stress in the Pathological Sequelae of Alzheimer Disease. , 1998, , 195-204.		2
817	Apoptosis and Alzheimer's Disease. , 1998, 282, 1265h-1265.		103
818	Is amyloid Î²-protein glycated in AlzheimerÊ¼s disease?. NeuroReport, 1997, 8, 907-909.	0.6	21
819	Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 9866-9868.	3.3	1,259
820	Levuglandin E2â˜Protein Adducts in Human Plasma and Vasculature. Chemical Research in Toxicology, 1997, 10, 536-545.	1.7	53
821	Mechanisms of Neurotoxicity Associated with Amyloid Î² Deposition and the Role of Free Radicals in the Pathogenesis of Alzheimer's Disease:â€‰ A Critical Appraisal. Chemical Research in Toxicology, 1997, 10, 518-526.	1.7	110
822	Protocol for quantitative analysis of paired helical filament solubilization: a method applicable to insoluble amyloids and inclusion bodies. Brain Research Protocols, 1997, 1, 247-252.	1.7	5
823	Widespread Peroxynitrite-Mediated Damage in Alzheimerâ€™s Disease. Journal of Neuroscience, 1997, 17, 2653-2657.	1.7	1,216
824	4â€Hydroxynonenalâ€Derived Advanced Lipid Peroxidation End Products Are Increased in Alzheimer's Disease. Journal of Neurochemistry, 1997, 68, 2092-2097.	2.1	892
825	APP transgenesis: Approaches toward the development of animal models for Alzheimer disease neuropathology. Neurobiology of Aging, 1996, 17, 153-171.	1.5	50
826	Early contribution of oxidative glycation in Alzheimer disease. Neuroscience Letters, 1996, 217, 210-211.	1.0	29
827	Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Research, 1996, 737, 195-200.	1.1	295
828	Î±-Calcium-Calmodulin-Dependent Kinase II is Associated with Paired Helical Filaments of AlzheimerÊ¼s Disease. Journal of Neuropathology and Experimental Neurology, 1996, 55, 954-963.	0.9	43

#	Article	IF	Citations
829	Elastase is associated with the neurofibrillary pathology of Alzheimer disease: a putative link between proteolytic imbalance and oxidative stress. Restorative Neurology and Neuroscience, 1996, 9, 213-217.	0.4	8
830	Quantitative solubilization and analysis of insoluble paired helical filaments from alzheimer disease. Brain Research, 1996, 717, 99-108.	1.1	63
831	Trypsin interaction with the senile plaques of Alzheimer disease is mediated by Î²-protein precursor. Molecular and Chemical Neuropathology, 1996, 27, 145-154.	1.0	14
832	Oxidative posttranslational modifications in Alzheimer disease. Molecular and Chemical Neuropathology, 1996, 28, 41-48.	1.0	62
833	Oxidative damage in Alzheimer's. Nature, 1996, 382, 120-121.	13.7	903
834	Amyloidosis, advanced glycation end products and Alzheimer disease. NeuroReport, 1995, 6, 1595.	0.6	25
835	Carbonyl-Related Modification of Neurofilaments in Aizheimer Disease. Journal of Neuropathology and Experimental Neurology, 1995, 54, 434.	0.9	0
836	Extracellular neurofibrillary tangles reflect neuronal loss and provide further evidence of extensive protein cross-linking in Alzheimer disease. Acta Neuropathologica, 1995, 89, 291-295.	3.9	139
837	Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid Î²-peptide. Nature Medicine, 1995, 1, 693-699.	15.2	416
838	Early AGEing and Alzheimer's. Nature, 1995, 374, 316-316.	13.7	69
839	Characterization of the association of phospholipase C-Î´ with Alzheimer neurofibrillary tangles. Brain Research, 1995, 669, 217-224.	1.1	20
840	Evidence for oxidative stress in Pick disease and corticobasal degeneration. Brain Research, 1995, 696, 268-271.	1.1	82
841	Alterations of low molecular weight acid phosphatase protein level in Alzheimer's disease. Brain Research, 1995, 699, 125-129.	1.1	14
842	Radical AGEing in Alzheimer's disease. Trends in Neurosciences, 1995, 18, 172-176.	4.2	469
843	Free radical damage, iron, and Alzheimer's disease. Journal of the Neurological Sciences, 1995, 134, 92-94.	0.3	113
844	Senile plaques and neurofibrillary tangles: The concurrent lesions of alzheimer's disease. Neurobiology of Aging, 1995, 16, 343-344.	1.5	1
845	Alteration of Phospholipase Câ€Î´ Protein Level and Specific Activity in Alzheimer's Disease. Journal of Neurochemistry, 1995, 64, 2629-2634.	2.1	25
846	Carbonylâ€Related Posttranslational Modification of Neurofilament Protein in the Neurofibrillary Pathology of Alzheimer's Disease. Journal of Neurochemistry, 1995, 64, 2660-2666.	2.1	211

#	Article	IF	Citations
847	Induction of Heme Oxygenaseâ€1 mRNA and Protein in Neocortex and Cerebral Vessels in Alzheimer's Disease. Journal of Neurochemistry, 1995, 65, 1399-1402.	2.1	199
848	Extracellular neurofibrillary tangles reflect neuronal loss and provide further evidence of extensive protein cross-linking in Alzheimer disease. Acta Neuropathologica, 1995, 89, 291-295.	3.9	22
849	Glial Cell Extracellular Matrix in Alzheimer's Disease. , 1995, , 158-170.		0
850	Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 7787-7791.	3.3	577
851	Advanced Maillard reaction end products are associated with Alzheimer disease pathology.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 5710-5714.	3.3	745
852	Advanced Maillard Reaction End Products, Free Radicals, and Protein Oxidation in Alzheimer's Disease^a. Annals of the New York Academy of Sciences, 1994, 738, 447-454.	1.8	134
853	Degeneration of vascular muscle cells in cerebral amyloid angiopathy of Alzheimer disease. Brain Research, 1993, 623, 142-146.	1.1	186
854	Rimmed vacuoles of inclusion body myositis and oculopharyngeal muscular dystrophy contain amyloid precursor protein and lysosomal markers. Brain Research, 1993, 603, 343-347.	1.1	47
855	Î±1-Trypsin Immunoreactivity in Alzheimer Disease. Biochemical and Biophysical Research Communications, 1993, 193, 579-584.	1.0	29
856	Chondroitin Sulfate Proteoglycans Are Associated with the Lesions of Alzheimer's Disease. Experimental Neurology, 1993, 121, 149-152.	2.0	163
857	Î²-Amyloid of Alzheimer's Disease Induces Reactive Gliosis That Inhibits Axonal Outgrowth. Experimental Neurology, 1993, 124, 289-298.	2.0	132
858	Abnormal accumulation of phospholipase C-Î´ in filamentous inclusions of human neurodegenerative diseases. Neuroscience Letters, 1993, 162, 183-186.	1.0	21
859	Ontogeny of the erythroid/HepG2-type glucose transporter (GLUT-1) in the rat nervous system. Developmental Brain Research, 1993, 72, 41-49.	2.1	42
860	Aberrant Phosphoinositide Metabolism in Alzheimer's Diseasea. Annals of the New York Academy of Sciences, 1993, 695, 46-49.	1.8	8
861	The Amyloid Precursor Protein in Ischemic Brain Injury and Chronic Hypoperfusiona. Annals of the New York Academy of Sciences, 1993, 695, 190-193.	1.8	75
862	Barrier properties of testis microvessels. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 11069-11073.	3.3	125
863	Î±1-Antitrypsin and Î±1-antichymotrypsin are in the lesions of AlzheimerÊ¼s disease. NeuroReport, 1992, 3, 201-203.	0.6	121
864	Basic fibroblast growth factor binds to filamentous inclusions of neurodegenerative diseases. Brain Research, 1992, 579, 350-352.	1.1	41

#	Article	IF	Citations
865	Serial reconstruction of Î²-protein amyloid plaques: relationship to microvessels and size distribution. Brain Research, 1992, 592, 278-282.	1.1	31
866	A Primate Model for Human Cerebral Malaria: Plasmodium coatneyi-Infected Rhesus Monkeys. American Journal of Tropical Medicine and Hygiene, 1992, 46, 391-397.	0.6	68
867	Demonstration of a novel neurofilament associated antigen with the neurofibrillary pathology of Alzheimer and related diseases. Brain Research, 1991, 558, 43-52.	1.1	15
868	Microglia are associated with the extracellular neurofibrillary tangles of alzheimer disease. Brain Research, 1991, 558, 312-314.	1.1	80
869	Tropomyosin distinguishes Lewy bodies of Parkinson disease from other neurofibrillary pathology. Brain Research, 1991, 541, 347-349.	1.1	24
870	Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 7552-7556.	3.3	244
871	Dementia with argyrophilic grains. Annals of Neurology, 1991, 30, 853-853.	2.8	19
872	Basic fibroblast growth factor binding is a marker for extracellular neurofibrillary tangles in Alzheimer disease.. Journal of Histochemistry and Cytochemistry, 1991, 39, 899-904.	1.3	60
873	Role of cytokeratin intermediate filaments in transhepatic transport and canalicular secretion. Hepatology, 1990, 11, 435-448.	3.6	38
874	Antigenic profile of plaques and neurofibrillary tangles in the amygdala in Down's syndrome: a comparison with Alzheimer's disease. Brain Research, 1990, 537, 102-108.	1.1	52
875	The widespread alteration of neurites in Alzheimer's disease may be unrelated to amyloid deposition. Annals of Neurology, 1989, 26, 771-778.	2.8	89
876	Immunochemical Properties of Ubiquitin Conjugates in the Paired Helical Filaments of Alzheimer Disease. Journal of Neurochemistry, 1989, 52, 1523-1528.	2.1	73
877	The presence of tau distinguishes Lewy bodies of diffuse Lewy body disease from those of idiopathic Parkinson disease. Neuroscience Letters, 1989, 100, 6-10.	1.0	55
878	Tau-reactive neurofibrillary tangles in cerebellar cortex from patients with Alzheimer's disease. Neuroscience Letters, 1989, 103, 259-262.	1.0	9
879	Soluble derivatives of the Î² amyloid protein precursor of Alzheimer's disease are labeled by antisera to the Î² amyloid protein. Biochemical and Biophysical Research Communications, 1989, 165, 182-188.	1.0	84
880	Immunoaffinity demonstration that paired helical filaments of Alzheimer disease share epitopes with neurofilaments, MAP2 and tau. Brain Research, 1989, 484, 150-156.	1.1	30
881	Influence of neuronal location on antigenic properties of neurofibrillary tangles. Annals of Neurology, 1988, 23, 604-610.	2.8	45
882	Alz 50 recognizes abnormal filaments in Alzheimer's disease and progressive supranuclear palsy. Annals of Neurology, 1988, 24, 407-413.	2.8	76

#	Article	IF	Citations
883	The glucose transporter of the human brain and blood-brain barrier. Annals of Neurology, 1988, 24, 757-764.	2.8	150
884	Paramyosin and actin in schistosomal teguments. Nature, 1988, 333, 76-78.	13.7	137
885	AMYLOID PRECURSOR PROTEIN IN SENILE PLAQUES OF ALZHEIMER DISEASE. Lancet, The, 1988, 332, 746.	6.3	71
886	Arachidonic acid metabolism in Ascidia ceratodes eggs: role of lipid peroxidation. Comparative Biochemistry and Physiology Part B: Comparative Biochemistry, 1988, 90, 785-789.	0.2	1
887	Ubiquitin is associated with abnormal cytoplasmic filaments characteristic of neurodegenerative diseases.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 4501-4505.	3.3	196
888	Phosphorylation of Neurofilaments Is Altered in Amyotrophic Lateral Sclerosis. Journal of Neuropathology and Experimental Neurology, 1988, 47, 642-653.	0.9	186
889	Hirano Body Filaments Contain Actin and Actin-Associated Proteins. Journal of Neuropathology and Experimental Neurology, 1987, 46, 185-199.	0.9	126
890	Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains.. Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 3033-3036.	3.3	586
891	Hirano bodies contain tau protein. Brain Research, 1987, 403, 337-340.	1.1	92
892	Antibodies to the neuronal cytoskeleton are elicited by Alzheimer paired helical filament fractions. Brain Research, 1987, 420, 233-242.	1.1	28
893	Coexistence of cytokeratin, vimentin and neurofilament protein in human choroid plexus. Virchows Archiv A, Pathological Anatomy and Histopathology, 1987, 410, 173-177.	1.4	34
894	Microtubules are not altered in the dystrophic chicken. Experimental Cell Research, 1986, 163, 266-272.	1.2	2
895	A STUDY OF ACTIN BINDING PROTEINS IN HIRANO BODIES. Journal of Neuropathology and Experimental Neurology, 1986, 45, 335.	0.9	1
896	Paired helical filaments from Alzheimer disease patients contain cytoskeletal components.. Proceedings of the National Academy of Sciences of the United States of America, 1985, 82, 3916-3920.	3.3	216
897	Characterization of a Ca2+-stimulated lipid peroxidizing system in the sea urchin egg. Developmental Biology, 1985, 107, 47-57.	0.9	36
898	Fertilization stimulates lipid peroxidation in the sea urchin egg. Developmental Biology, 1985, 107, 58-65.	0.9	40
899	Interaction of Calcium-Calmodulin in Microtubule Assembly in Vitro. , 1982, , 73-84.		3
900	Ca2+-stimulated production of H2O2 from naphthoquinone oxidation in Arbacia eggs. Experimental Cell Research, 1981, 134, 65-72.	1.2	40

#	Article	IF	Citations
901	Cytochalasin B blocks sperm incorporation but allows activation of the sea urchin egg. Experimental Cell Research, 1980, 126, 333-342.	1.2	38
902	Oxidative Damage and Antioxidant Responses in Alzheimer's Disease. , 0, , 371-378.		2
903	Neuroinflammatory Responses in the Alzheimer's Disease Brain Promote the Oxidative Post-translational Modification of Amyloid Deposits. , 0, , 341-361.		14
904	Phosphorylation, Microtubule Binding and Aggregation of Tau Protein in Alzheimer's Disease. , 0, , 601-607.		0
905	La funciÃ³n del estrÃ©s oxidativo en la patogÃ©nesis de la enfermedad de Alzheimer. Revista Chilena De Neuro-Psiquiatria, 0, 41, .	0.0	0